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Medulloblastoma is a developmental cancer of the cerebellum. It continues to be the most 
common pediatric brain cancer associated with dire survival and impaired quality of life. In 
order to develop therapeutic interventions, it is necessary to bridge the gaps in knowledge 
about cerebellar development and understand how aberrations in developmental pathways 
lead to cancer. The Sonic hedgehog pathway (Shh) plays a pivotal role in cerebellar 
development and mutations leading to hyperactive signaling cause medulloblastoma. 
Although the fundamentals of the pathway mechanics are known, and have led to the 
development of mouse models to study the human disease, there are critical questions that 
remain to be answered. Based on pathway signatures medulloblastomas are categorized into 
subgroups, Shh-driven being one such subgroup. However there is significant heterogeneity 
even among Shh-driven medulloblastomas that necessitates understanding key differences 
between the various mutations and differential regulation of downstream effectors. Through 
the characterization of a novel mouse model of medulloblastoma, SmoA2 and comparative 
!analyses with the existing SmoA1 model, I have demonstrated salient molecular and cellular 
differences between two activating mutations in the same region of a single gene. While the 
SmoA1 mutation leads to medulloblastoma in adult mice, in addition to cancer, the SmoA2 
mutation causes severe defects early in cerebellar development.  The transcriptional profiles 
downstream of these two mutations and biological processes affected are distinct. An 
unexpected finding from the SmoA2 model is the preservation of normal cerebellar function 
despite a completely disrupted cytoarchitecture challenging the notion that stereotypical 
organization of the cerebellum is critical for its function. My second aim was to identify 
molecules that interact with the Shh pathway in development and disease. Toward this goal, I 
discovered a previously unknown expression pattern of MyoD in the proliferative phase of 
the developing cerebellum as well as in mouse medulloblastoma. MyoD, a myogenic 
differentiation factor has been known to be exclusive to the skeletal muscle lineage. I 
demonstrate MyoD functions as a novel haploinsufficient tumor suppressor in the context of 
medulloblastoma with potential clinical significance.  
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Chapter 1 
Introduction 
The Cerebellum and its Development 
The cerebellum (Latin: little brain) constitutes only 10% of the total brain in volume 
yet consists of more than half the total number of neurons. This reflects its neuronal 
complexity as well as functional importance as a central nervous system structure (Wang and 
Zoghbi, 2001). In addition to its classic functions in motor coordination and balance, recent 
studies reveal a role for the cerebellum in higher cognitive processes that include sensory-
motor learning, speech and spatial memory (Hatten and Roussel, 2011). The development of 
the cerebellum is unique compared to the rest of the brain. It consists of distinct prenatal and 
postnatal phases that include intricately regulated processes of cell specification, 
proliferation, differentiation, regression and migration (Selvadurai and Mason, 2011).  
 
Cells of the Cerebellum 
The cerebellum has a unique laminar cytoarchitecture consisting of the outermost 
molecular layer, the Purkinje cell monolayer, the internal granule layer (IGL) and an inner 
most region of white matter. The cells of the cerebellum arise from two germinal matrices – 
the Purkinje cells, cells of the deep cerebellar nuclei and the modulatory neurons (stellate, 
Golgi and basket) originate from the ventricular zone while the granule neuron precursors 
(GNPs) and some cells of the deep cerebellar nuclei are born in the rhombic lip (Wang and 
Zoghbi, 2001). The granule neurons and the Purkinje cells function as the cerebellar sensory 
input and motor output respectively. The granule neurons transmit sensory information from 
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the periphery to the Purkinje cells (Wang and Zoghbi, 2001). The Purkinje cells via the deep 
cerebellar nuclei transmit this information to the motor cortex for fine-tuning of movement 
and balance. The other neuronal types modulate the activity of the Purkinje cells (Wang and 
Zoghbi, 2001). Although the above is a simplistic representation, this basic circuitry 
underlies the function of the cerebellum as a motor coordination center.  
Granule neuron precursors are born around embryonic day (E)10.5 in mice and 
migrate circumferentially along the cerebellar anlage between E12.5-E15.5 to form the 
transient external granule layer (EGL) (Zindy et al., 2006).  In the postnatal phase, the GNPs 
undergo massive expansion in response to the mitogen Sonic hedgehog (Shh) secreted by the 
overlying Purkinje cells. The GNPs reach their peak of proliferation between postnatal day 
(P) 5-P8 in mice (Fujita, 1967). This unique protracted proliferative phase predisposes the 
cerebellum to various developmental anomalies as well as neoplastic changes (Wang and 
Zoghbi, 2001). The cells in the inner EGL then exit the cell cycle and undergo inward radial 
migration to form the IGL of the adult cerebellum. This process is complete by about P21 in 
mice and a year after birth in humans (Wang and Zoghbi, 2001).  
The Purkinje cells are born around E13, exit mitosis by E14 and migrate along radial 
glia into the cerebellar anlage (Wang and Zoghbi, 2001). The cells then become suspended 
beneath the EGL. Initially the Purkinje cells are organized into a multi-layered structure but 
around the time of birth disperse into a single monolayer (Sillitoe and Joyner, 2007). This 
layer undergoes further maturation developing extensive dendritic arbors and making 
appropriate synaptic connections with incoming afferents, a process that is complete by P15 
(Wang and Zoghbi, 2001; Sillitoe and Joyner, 2007). 
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Neuronal migration in the cerebellum 
The defined cytoarchitecture, limited diversity in neuronal types and the protracted 
postnatal development make the cerebellum an excellent model system for studying neuronal 
migration which include circumferential, radial and tangential migration pathways 
(Goldowitz and Hamre, 1998). In this section, I present an overview of some of the major 
neuronal migration systems involving granule neurons and Purkinje cell, that play key roles 
in the developing cerebellum.  
The GNPs in the rhombic lip proliferate and then begin to migrate dorsally over the 
roof of the cerebellar anlage to form the EGL between E12-E15 (Wang and Zoghbi, 2001; 
Hatten, 2002). UNC6/Netrin1 and its receptors are critical for early cell migration events in 
the cerebellum, acting as a chemorepellant for the EGL cells and a chemoattractant for the 
precerebellar nuclei progenitors (Hatten, 2002). GNPs in the outer EGL undergo massive 
expansion and then migrate into the inner EGL where they are in a post mitotic state. At this 
stage, the GNPs undergo tangential migration, possibly to ensure appropriate distribution 
across parasagittal compartments of the expanding cerebellar cortex (Komuro et al., 2001). 
The chemokine Cxcl12/Stromal derived growth factor (Sdf)-1α secreted from the pia mater 
(one of the three meninges lining the central nervous system) and its receptor Cxcr-4 
expressed in the EGL help in retaining the GNPs in the EGL thereby preventing premature 
migration (Klein et al., 2001). 
The next phase involves GNP migration to the IGL under the guidance of radial glial 
(Bergmann glia) fibers. One of the factors shown to be important in preparing the cells for 
this phase is N-methyl-D-aspartate (NMDA) subtype of glutamate receptors-mediated 
depolarization followed by compensatory hyperpolarization by inward rectifying K+ channel, 
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GIRK2 (Wang and Zoghbi, 2001).  During glial-guided migration, the cytoskeletal 
organization of the cells is also critical (Hatten, 2002). In addition, several proteins play key 
roles in the glia-guided migration of GNPs including Astrotactin (acts as a heterophilic 
ligand for glial binding), Thrombospondin (involved in axon extension during migration), 
Tenascin (promotes neurite outgrowth and migration) and Neuregulin (expressed in GNPs 
that bind to ErbB4 on the glial cell during migration) (Wang and Zoghbi, 2001).  
The proper migration of the Purkinje cells depends on the Reelin pathway, a protein 
secreted by cells in the EGL. Mutations in the Reelin gene or any of the downstream 
components in its signaling pathway cause various cerebellar migration defects as observed 
in the reeler and scrambler neurological mouse mutants (Rice and Curran, 1999). 
 
Bi-directional cellular interactions in the cerebellum 
The final maturation phase of the Purkinje cells when they develop extensive 
dendritic arbors and synapse onto granule neurons depends on signals from the latter (Wang 
and Zoghbi, 2001).  In mutants such as weaver that lack granule neurons, the dendritic trees 
of Purkinje cells do not form (Rakic and Sidman, 1973) and in in vitro experiments, Purkinje 
cells need to be co-cultured with granule neurons for proper development (Baptista et al., 
1994). Granule neurons with mutations in the Netrin receptor migrate to ectopic locations 
and attract Purkinje cells and other cell types resulting in abnormal migration of the latter as 
well (Goldowitz and Hamre, 1998). Whether the influence of granule neurons on Purkinje 
cells is via specific molecules or through electrical activity or a combination of both is yet to 
be fully understood. Although the migration of Purkinje cells depends on signals from GNPs, 
the differentiation program is independent of granule neurons, since mutants that lack GNPs, 
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have normally differentiated Purkinje cells (Jensen et al., 2002). On the other hand, 
perturbation of Purkinje cells lead to loss in granule neuron numbers (Smeyne et al., 1995). 
In reeler and scrambler mutants, the abnormal migration of Purkinje cells compromises 
granule cell numbers and subsequently affects foliation (Rice and Curran, 1999).  
Bidirectional interactions also exist between radial glia and granule neurons which 
include neuron-glial trophic signals as well as glial-neuron buffering of the surrounding 
environment (Goldowitz and Hamre, 1998). 
 
Foliation and Cerebellar Circuitry 
The cerebellum has a unique morphological structure consisting of folia with fissures 
separating its anterior-posterior extent into lobules (Sillitoe and Joyner, 2007). The folia 
putatively serve as a platform for organizing cerebellar circuits (Sudarov and Joyner, 2007). 
Specific gene expression patterns in the Purkinje cells along parasagittal stripes molecularly 
code each lobule along the medial-lateral axis (Sudarov and Joyner, 2007). Afferent inputs 
from outside the cerebellum via climbing fibers and from within the cerebellum via granule 
neurons axon synapse onto the Purkinje cells (Chizhikov and Millen, 2003). The current 
understanding of cerebellar function is that these afferents carrying synchronized sensory-
motor information terminate onto specific parasagittal domains in a pattern that mirrors the 
Purkinje cell molecular coding thereby compartmentalizing the cerebellum into distinct 
functional modules (Chizhikov and Millen, 2003; Sillitoe and Joyner, 2007).   
Cerebellar foliation is genetically determined and results from coordinated cell 
movements and structural changes (Sudarov and Joyner, 2007). The process can be divided 
into two stages – the embryonic stage which involves formation of fissures at ~ E17 dividing 
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the cerebellum into cardinal lobes (Sillitoe and Joyner, 2007). By birth a rudimentary set of 
synaptic connections are established that are topographically organized in the context of the 
anterior-posterior folds and the medial-lateral molecular coding (Sillitoe and Joyner, 2007). 
The second postnatal stage involves extensive outgrowth of the cardinal lobes and further 
subdivision into lobules and sub lobules (Sudarov and Joyner, 2007). By P15, the cellular 
layers and the complete set of ten folia in mice (designated as I to X) are fully formed with 
specific cerebellar circuits that correlate the lobular morphology with the molecular domains 
(Sillitoe and Joyner, 2007).  
The cellular and genetic basis of foliation initiation is not well understood. According 
to a new cellular model proposed by Sudarov and Joyner, the GNPs are responsible for 
providing the physical force through the formation of multicellular “anchoring centers” at the 
base of each fissure that consists of Purkinje cells, GNPs and Bergmann glia, between E16.5-
E18.5 (Sudarov and Joyner, 2007). The outgrowth of folia then continues through a self-
sustaining process involving coordinated actions of GNPs and Bergmann glia (Sudarov and 
Joyner, 2007). 
 
Signal transduction pathways in cerebellar development 
A number of signal transduction pathways play critical roles in the cerebellum during 
normal development as well as pathological conditions. These pathways include Notch, 
Wnt/beta-catenin, Bone morphogenetic proteins (BMP) and Sonic hedgehog (Shh) (Hatten 
and Roussel, 2011). My dissertation research involves the Shh pathway, which I describe in 
detail in this section. 
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Sonic hedgehog pathway in granule neuron precursor proliferation and foliation 
The Shh ligand secreted by the Purkinje cells around E17 is responsible for the high 
degree of proliferation of GNPs in the postnatal phase of cerebellar development in the EGL 
(Wechsler-Reya and Scott, 1999; Hatten and Roussel, 2011) that causes the cerebellum in 
increase over a 1000-fold in volume (Corrales et al., 2006) (Figure 1.1A). Perturbations to 
Purkinje cells can result in a devastating decline in granule neuron numbers as observed in 
various mutant mouse models (Goldowitz and Hamre, 1998). Interestingly, although Shh is 
expressed in the cerebellum through out life, Shh-induced proliferation of GNPs occur only 
in the early postnatal period exclusively in the EGL (Rubin et al., 2002). This mitogenic 
niche is created in part by the anatomic localization of factors like heparan sulphate 
proteoglycans (Rubin et al., 2002), Sdf-1α (Klein et al., 2001), laminin and Notch2 that 
interact with the Shh pathway and are critical determinants of GNP expansion (Rubin et al., 
2002). In addition, the Shh concentration gradient and the resulting dose-response to Shh-
induced proliferation play a key role in this spatiotemporal regulation of GNP expansion 
(Rubin et al., 2002).  
The Shh pathway is also important for development of Bergmann glia, a critical 
component in the migration of GNPs. Shh induces differentiation of Bergmann glia and 
aberrations in Shh signaling lead to disorganized glial fibers (Corrales et al., 2006; Vaillant 
and Monard, 2009).   
The Shh pathway plays a critical role in cerebellar foliation by driving GNP 
proliferation (Corrales et al., 2004; Corrales et al., 2006). Graded increases in Shh signaling   
through genetic manipulations in mice show that in addition to a thicker and irregular IGL 
resulting from increased GNP proliferation, these mice show increased folia length, 
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additional bulges in the IGL and even an extra sub-lobule, the extent of foliation being 
proportional to the degree of Shh signaling (Corrales et al., 2006). Reducing Shh signaling by 
conditional knockout of Smo or Gli2, activators of the pathway, result in simpler foliation 
patterns (Corrales et al., 2006). In both cases, the patterns of foliation along the 
anteroposterior and mediolateral axes are the same as the conserved pattern which suggests 
that Shh does not determine the position of the fissures, but is a permissive factor for 
foliation (Sillitoe and Joyner, 2007). 
 
Mechanics of the vertebrate Sonic Hedgehog pathway 
The eukaryotic primary cilium, a microtubule based membrane extension assembled 
and maintained by bidirectional intraflagellar transport, plays a critical role in Shh signaling 
in vertebrate cells by aiding in the concentration of various components of the pathway 
(Rohatgi et al., 2007; Spassky et al., 2008; Wen et al., 2010).  In vertebrates, Gli1, Gli2 and 
Gli3 are the main activators of the pathway. Gli2 and Gli3 when processed, can function as 
repressors when the Shh pathway is inactive (Wen et al., 2010).  In the absence of the ligand 
Shh, Patched 1 (Ptch1), a twelve-transmembrane domain protein, located on the cell 
membrane in the cilia, represses the activity of the seven-transmembrane domain protein 
Smoothened (Smo) (Lum and Beachy, 2004; Cohen, 2010; Hui and Angers, 2011; Markant 
and Wechsler-Reya, 2011) presumably by preventing its cell surface localization from 
intercellular endosomes (Denef et al., 2000; Rubin and de Sauvage, 2006) (Figure 1.1Bi). 
There are a few different models describing the mechanics of the Shh pathway. One model 
suggests that a yet uncharacterized small molecule agonist of Smo is potentially transported 
outside the cell by Ptch1 thereby preventing its binding to Smo (Rubin and de Sauvage, 
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2006). Additionally, various kinases phosphorylate Gli3 (Gli1, Gli2, Gli3: the activators of 
the pathway), which is then cleaved into a repressor form, GliR. GliR translocates to the 
nucleus and inhibits activation of downstream targets. Iguana and SUFU sequester the active 
form of Gli proteins (GliA) preventing nuclear translocation.  In the presence of Shh, binding 
of the ligand to Ptch1 causes internalization and subsequent destabilization of Ptch1 (Figure 
1.1Bii). The endogenous ligand of Smo then activates Smo (Rubin and de Sauvage, 2006) 
causing its translocation to the ciliary surface along with the unprocessed Gli proteins (Corbit 
et al., 2005; Wen et al., 2010). Intraflagellar transport proteins play a key role in this 
translocation (Huangfu and Anderson, 2006). Smo-mediated activation of the Gli proteins 
cause them to translocate from the cilia to the nucleus where Shh target genes are activated. 
Thus, Shh, Smo and Gli proteins activate the pathway whereas Ptch and SUFU function as 
repressors.  
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A       B (i)  
 
 
 
 
 
 (ii)  
 
 
 
 
 
 
 
 
 
Figure 1.1  
Mechanics of the vertebrate Shh signaling pathway 
A. During early postnatal development of the mouse cerebellum, the Sonic hedgehog (Shh) protein secreted from the 
Purkinje cells promotes the proliferation of the granule neuron precursors in the outer external granule layer (EGL). The 
post mitotic GNPs then migrate from the inner EGL to the internal granule layer guided by radial glial processes (Bergmann 
glia). Shh also induces the maturation of Bergmann glia. Figure taken from (Ruiz i Altaba et al., 2002). 
B (i) In the absence of Shh, its receptor Patched1 (Ptch1), located on the plasma membrane inhibits the G-protein coupled 
receptor, Smoothened (Smo) by possibly exporting an endogenous agonist of Smo outside the cell. Different kinases 
phosphorylate Gli2/3 creating a repressor form of this transcription factor (GliR). Iguana and SUFU prevent the active form 
of Gli (GliA) from trans activating Shh-responsive genes. 
(ii) Upon binding of Shh, Ptch1 is internalized relieving the inhibition on Smo, which then translocates from the intracellular 
endosomes to the cilia of the plasma membrane. It then engages yet unknown components of the signaling pathway, which 
culminates in activating the Gli proteins, which regulate the expression of Shh target genes.  
Figure taken from (Rubin and de Sauvage, 2006)  
 
 
 
 
 
!
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Medulloblastoma 
Medulloblastoma is an embryonal tumor of the cerebellum and the most common 
pediatric brain malignancy (Gilbertson and Ellison, 2008). Although current treatment 
strategies including chemotherapy, radiation and surgical resection lead to significantly 
improved survival (Crawford et al., 2007), approximately one-third patients remain incurable 
and those who survive experience drastic neurocognitive sequelae (Wolfe-Christensen et al., 
2007) (Saury and Emanuelson, 2011).  
Medulloblastoma is a highly heterogeneous tumor that is classified into distinct 
histological subtypes which according to the 2007 WHO classification, are - classic, 
desmoplastic, anaplastic, large-cell medulloblastomas and medulloblastoma with extensive 
nodularity (Gilbertson and Ellison, 2008). A rare histological variant of medulloblastoma, 
medullomyoblastoma, that presents with myogenic differentiation, was first described in 
1933 (Er et al., 2008). The molecular basis of this rare pathological feature is yet to be 
determined and is initiated by my work described in Chapter 3. 
Gene expression studies of human medulloblastomas have led to identification of four 
distinct molecular subgroups (Thompson et al., 2006; Kool et al., 2008; Cho et al., 2011; 
Northcott et al., 2011a; Sengupta et al., 2011; Taylor et al., 2011).  These subgroups are 
characterized by aberrations in (i) WNT signaling (ii) SHH signaling (iii) MYC amplification 
and a fourth heterogeneous group with yet unknown genetic determinants. Two distinct 
progenitor populations – GNPs (Schuller et al., 2008; Yang et al., 2008) and cells of the 
lower rhombic lip (Gibson et al., 2010) have been identified as cells of origin through lineage 
tracing and genetic analyses in mouse models of medulloblastoma. Medulloblastomas arising 
from GNPs frequently have mutations leading to constitutive SHH signaling (SHH-subtype) 
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while those that arise from the cells of the lower rhombic lip have activating mutations in the 
WNT pathway effector CTNNB1 (WNT-subtype). There is also marked clinical difference 
between the WNT and SHH subgroup medulloblastomas. The WNT subtype 
medulloblastomas have classic histology, occur in older children and are highly curable as 
opposed to the SHH subtype tumors which includes desmoplastic as well as anaplastic large 
cell histology (Gibson et al., 2010; Sengupta et al., 2011), is predominant in babies and 
young adults with mixed prognosis (Taylor et al., 2011).  My dissertation was aimed at 
furthering our understanding of the Shh pathway in cerebellar development and disease and 
hence I focus on the Shh-driven subgroup in the section below.  
 
Sonic Hedgehog-driven medulloblastoma 
The importance of the SHH pathway in medulloblastoma was first recognized 
following the discovery that patients with Gorlin’s syndrome, a hereditary disease with 
increased incidence of basal cell carcinoma and medulloblastoma, carried heterozygous 
germline mutations in PTCH1 (Goodrich et al., 1997). Sporadic mutations, which include 
inactivating mutations in PTCH1, SUFU and activating mutations in SMO, are observed in 
20-30% of medulloblastoma cases predominantly in infants  (< 3 years of age) and adults, 
but rarely in children showing heterogeneity in age of onset (Cho et al., 2011; Northcott et 
al., 2011a). The prognosis for the SHH-subtype of medulloblastoma is mixed (Gajjar et al., 
2006; Thompson et al., 2006; Kool et al., 2008). Although, SHH-driven medulloblastomas 
have been associated with the desmoplastic histology (Pietsch et al., 1997; Pomeroy et al., 
2002), this cannot be used as a prognostic indicator as shown by large-scale genomic studies 
where other histological variants may also present with SHH pathway signatures (Cho et al., 
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2011; Markant and Wechsler-Reya, 2011; Northcott et al., 2011a). 
GNPs with constitutive activation of Shh signaling are known to be the cellular 
source of Shh driven medulloblastomas (Gilbertson and Ellison, 2008). However, the 
histological heterogeneity makes it possible that different subpopulations of GNPs lead to 
distinct types of tumors even within the Shh driven class of medulloblastomas (Hatten and 
Roussel, 2011).  Interestingly, studies from the GENSAT project, a large-scale CNS gene 
expression atlas that has generated more than 600 transgenic mouse lines expressing 
Enhanced Green Fluorescent Protein (EGFP) reporter genes in a variety of CNS cell types, 
have identified genes expressed in a subset of GNPs at specific developmental stages (Gong 
et al., 2003). This suggests the possibility that distinct subsets of GNPs that may have 
different susceptibilities to neoplastic transformations (Hatten and Roussel, 2011) that 
potentially contributes to the high degree of heterogeneity even in the same SHH subtype of 
medulloblastomas. 
 
Co-acting pathways in Sonic Hedgeghog driven Medulloblastoma   
 Activation of the Shh pathway alone does not explain medulloblastoma biology even 
within the SHH subgroup (Sengupta et al., 2011). The histological heterogeneity observed 
within the SHH group could be a result of different molecular mechanisms underlying 
tumorigenesis. The fact that medulloblastoma prone progenitor cells engineered to have 
constitutive Shh signaling can undergo normal cell cycle exit and differentiation and only a 
subset of these cells give rise to tumors suggests the presence of additional factors that keep 
the latter in a proliferative state (Ayrault et al., 2010). Only 14-20% of the preneoplastic 
lesions nullizygous for Ptch1 develop into medulloblastomas in the Ptch1 heterozygous 
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mouse model, underscores the importance of additional events that enhance the effect of the 
initial Shh pathway mutation and are necessary for tumorigenesis (Sengupta et al., 2011). 
The vast majority of molecules that functionally interact with the SHH pathway as tumor 
suppressors or oncogenes in medulloblastoma genesis are unknown and need to be identified 
to devise therapeutic strategies that take into account the molecular and cellular tumor 
heterogeneity (Markant and Wechsler-Reya, 2011).   Outlined below are examples of some 
known pathways conserved in cerebellar development and tumorigenesis that functionally 
interact with the Shh pathway synergizing or antagonizing its effects. 
 
CXCL12-CXCR4 pathway 
The chemokine CXCL12/Stromal derived factor (SDF)-1α secreted from the pia 
mater enhances SHH-induced proliferation of GNPs as well as proper migration during 
normal cerebellar development. A recent study by Sengupta et al shows that SHH driven 
medulloblastomas can be further subdivided into CXCR4 high and low expresser groups 
which have their distinct molecular, histological and epidemiological profiles (Sengupta et 
al., 2011). While CXCR4 potentiates Shh driven GNP as well as tumor growth, SHH 
modulates CXCR4 signaling by regulating its cell surface expression. The synergism 
between these two signaling pathways that lead to maximal tumor growth defines a new 
molecular subgroup within the SHH-driven medulloblastomas that may benefit from 
therapeutic interventions that target both pathways(Sengupta et al., 2011).  
Hippo pathway/ Yes-associated protein (YAP)-1 
Fernandez-L et al. demonstrate a functional interaction between the Hippo tumor 
suppressor pathway and Shh signaling. YAP1, that is normally repressed by the Hippo 
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pathway is overexpressed and amplified in both mouse and human medulloblastoma with 
aberrant Shh signaling (Fernandez et al., 2009). Shh induces YAP1 expression and nuclear 
localization that drive GNP proliferation during normal development as well as expansion of 
tumor cells in the perivascular niche where tumor re-populating cells persist (Fernandez et 
al., 2009) 
Atoh1/Math1          
 Math1 (Atoh1), a basic helix loop helix transcription factor, is important for the 
generation of cerebellar granule neurons (Ben-Arie et al., 1997). It is expressed in the 
proliferating GNPs in the developing EGL and over-expressed in medulloblastomas that have 
increased Shh signaling. Although insufficient to support proliferation in the absence of Shh, 
by inhibiting neuronal differentiation genes, Math1 maintains GNPs in a Shh-responsive state 
and promotes Shh/Gli1 induced transformation of GNPs into medulloblastomas (Ayrault et 
al., 2010). However, Math1 is not purely a proliferation factor as demonstrated by Klisch et 
al, where Math1 is also necessary for the initiation of the differentiation program in the EGL 
cells (Klisch et al., 2011). Interestingly, Math1 promotes proliferation in the cerebellum and 
acts as an oncogene in medulloblastoma but enhances cell cycle exit and acts as a tumor 
suppressor in intestinal tumors (Klisch et al., 2011)    
Insulin Growth Factor (IGF) signaling  
IGF-2 synergizes the effect of Shh on proliferating GNPs (Hartmann et al., 2005) and 
is often upregulated in desmoplastic human medulloblastoma (Pomeroy et al., 2002). Mouse 
studies demonstrate that IGF-2 and the Shh pathway synergize to induce medulloblastoma 
formation (Hahn et al., 2000; Pomeroy et al., 2002; Rao et al., 2004) 
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Hypermethylated in cancer (HIC) 1 
HIC1 is at the17p13.3 chromosomal locus, a region frequently deleted in 
medulloblastoma (Ferretti et al., 2005). In mice, Hic cooperates with Ptch1 to silence Atoh1 
which is important for GNP proliferation during cerebellar development. The loss of Hic1 
accelerates tumor incidence in the Ptch1 heterozygous medulloblastoma model (Briggs et al., 
2008). 
Fibroblast growth factor (FGF) 
Fibroblast growth factor 2 (FGF-2) antagonizes the proliferative effect of Shh on 
GNPs, yet on its own stimulates proliferation (Wechsler-Reya and Scott, 1999; Fogarty et al., 
2007). FGF has also been shown to impair growth of human medulloblastoma cells in vitro 
as well as in xenograft models (Duplan et al., 2002; Vachon et al., 2004) 
Bone Morphogenetic Protein (BMP) signaling 
A balance between the Shh and BMP signaling pathways regulate proliferation and 
differentiation of GNPs in the EGL. BMPs are important for initiating the granule neuron 
specification program in the cerebellum (Alder et al., 1999). BMP-2 and BMP-4 inhibit Shh-
induced medulloblastoma (Alder et al., 1999) and BMP-2 regulates retinoid-induced 
apoptosis of medulloblastoma (Hallahan et al., 2003)  
 
MicroRNAs in cerebellar development and medulloblastoma   
 microRNAs (miRNAs) are a class of non-coding small RNAs that regulate gene 
expression post-transcriptionally. miRNAs bind to the 3’ UTRs of target mRNAs and inhibit 
subsequent transcription. miRNAs play critical roles in many aspects of development 
regulating proliferation and differentiation (Ferretti et al., 2008) including in the brain, which 
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is a major site of miRNA expression (Olsen et al., 2009; Hatten and Roussel, 2011). Various 
miRNAs have been implicated in neuronal morphogenesis, synaptic functions, neuronal 
differentiation, circadian clock modulation and Purkinje cell maintenance among others 
(Olsen et al., 2009). 
Misregulations of miRNAs are linked to cancer (Calin and Croce, 2006). In 
medulloblastoma, various miRNAs have been shown to be up-regulated with potential 
oncogenic functions, while those that are down-regulated function as tumor suppressors 
(Hatten and Roussel, 2011). The miR 17~92 cluster has been shown to be upregulated by two 
independent studies although the targets remain to be identified (Northcott et al., 2009; Uziel 
et al., 2009). The up-regulation of miR 17~92 is also associated with a loss of a normal allele 
of Ptch1 suggesting a functional interaction between the miR 17~92 cluster and Shh 
signaling in medulloblastomas genesis (Uziel et al., 2009). Another study with the help of 
high-throughput screening of miRNAs in distinct subsets of medulloblastomas, led to the 
identification of miRNAs involved in Shh signaling (Ferretti et al., 2008). miR-125b, miR-
324-5p and miR-326 were found to be down regulated in Shh-driven medulloblastomas. The 
mRNA targets were shown to be the activators of the Shh signaling pathway – SMO and 
GLI1. Interestingly, the same set of miRNAs is down regulated in normal proliferating GNPs 
where a high level of Shh signaling is required. As the GNPs differentiate, the miRNA levels 
increase to antagonize the Shh pathway and inhibit proliferation (Ferretti et al., 2008).  
Although a large number of miRNAs are expressed in the brain, the function of most, 
remain to be elucidated. Several miRNAs are also associated with neurological and 
psychiatric diseases like schizophrenia (Hansen et al., 2007), Parkinson’s disease (Kim et al., 
2007), X-linked mental retardation suggesting that miRNAs are functionally important not 
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just in the developing nervous system, but in adulthood as well (Mehler and Mattick, 2006; 
Olsen et al., 2009). A study by Olsen et al. identified spatially restricted patterns of miRNA 
expression in the adult rat brain indicating their potential involvement in maintaining area-
specific brain functions (Olsen et al., 2009). The cerebellum was shown to have either high 
enrichment for a set of miRNAs (miR-206 and miR-497) or depletion of others (miR-132, 
miR-212, miR-221 and miR-222). Intriguingly, miR-206 known to be an important skeletal-
muscle specific miRNA (Rosenberg et al., 2006), has also been shown to function as a tumor 
suppressor in certain types of cancers (Kondo et al., 2008; Song et al., 2009; Taulli et al., 
2009). miR-206 was also one of 24 miRNAs down regulated in proliferating mouse GNPs as 
well as medulloblastomas when compared to mature mouse cerebellum (Uziel et al., 2009). 
This finding is indicative of a potential tumor suppressor role of miR-206 in the cerebellum 
as well. The exact significance of miR-206 enrichment in the cerebellum remains to be 
determined.  
These findings demonstrate that miRNAs play an important role in the nervous 
system both to modulate key developmental pathways (e.g. Shh signaling) as well as for 
maintaining critical functions in adulthood. Aberrations in miRNA expression and function 
can lead to cancer and neuropathological conditions.  
 
Mouse models of medulloblastoma 
The Shh-driven subtype of medulloblastoma is the most studied with the vast majority of the 
existing mouse models recapitulating this subtype (Hatten and Roussel, 2011). The Ptch1-
heterozygous knock out model was the first genetically engineered mouse model of 
medulloblastoma (Goodrich et al., 1997). The existing models of medulloblastoma have 
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various genetic anomalies that lead to aberrant activation of Shh signaling. These include 
mutations in components directly involved in Shh signaling such as mutations in Smo, Sufu, 
loss of Ptch1 alone or accompanied by loss of cell cycle regulators p18INK4c or p27Kip1 as well 
as molecules not directly in the pathway such as loss of Rb, loss of DNA repair enzymes 
Brca2, Parp, Xrcc often in combination with the loss of Trp53 (Hatten and Roussel, 2011; 
Markant and Wechsler-Reya, 2011).  The fact that mutations in molecules not directly 
involved in Shh signaling lead to tumors resembling Shh-driven tumors at a molecular level 
underscores the importance of this pathway in medulloblastoma genesis. It also implicates 
that some SHH-driven human medulloblastomas may be initiated by mutations in interacting 
pathways (Markant and Wechsler-Reya, 2011).  
These mouse models have provided critical information about medulloblastoma 
biology and created opportunities to study the molecular and pathological basis of this 
cancer. The mouse model with activating mutation SmoA1 develops medulloblastoma and 
the Smo/Smo model (homozygous for activating mutation SmoA1) is the first to develop 
leptomeningeal dissemination (i.e. metastasis to the meninges covering the brain and the 
spinal cord) a feature common in human medulloblastoma (Hallahan et al., 2004; Hatton et 
al., 2006). The recent Ptch1 conditional knock out model has established that GNPs are the 
cell of origin for Shh driven medulloblastomas (Yang et al., 2008). A 100% tumor incidence 
and a short time to tumor onset make this model ideal for preclinical trials. The Shh-
medulloblastoma models have been invaluable in identifying cooperating pathways namely 
N-myc, IGF-1, Akt, Bcl-2, hepatocyte growth factor, Hippo pathway, CXCR4 among others 
thereby initiating efforts to therapeutically target multiple pathways for the most effective 
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inhibition of tumorigenesis (Briggs et al., 2008; Fernandez et al., 2009; Markant and 
Wechsler-Reya, 2011; Sengupta et al., 2011). 
The Wnt driven medulloblastomas are recapitulated by a recent model which 
conditionally expresses activated beta-catenin in collaboration with the loss of Trp53 in cells 
of the cerebellar ventricular zone and lower rhombic lip (Gibson et al., 2010), the cell of 
origin for this subtype (Gilbertson and Ellison, 2008).  
It is interesting to note that a number of mouse models of medulloblastoma require a 
loss of Trp53 (Hatten and Roussel, 2011) while only 10% of human medulloblastomas lack 
Trp53 (Thompson et al., 2006) suggesting that there might be certain molecular differences 
between mouse and human tumorigenesis (Hatten and Roussel, 2011).  
Models representing the MYC subgroup, the most aggressive subtype of human 
medulloblastomas, as well as the unspecified genetic group, are yet to be established. A 
novel Non-Shh/Non-Wnt mouse model was recently developed by expressing MYCN in 
multiple cerebellar progenitors (Swartling et al., 2010). These mice develop aggressive 
tumors, the majority of which do not have a Shh pathway signature. The correlation of this 
model with the human medulloblastoma subgroups is yet to be determined. 
 
Aim of my Dissertation Research 
The goal of my dissertation research was to understand the molecular mechanisms 
underlying the roles played by the Shh pathway in cerebellar development and 
medulloblastoma. The two areas I have been interested in are (i) heterogeneity in Shh driven 
medulloblastomas and (ii) genes and/or pathways that interact with Shh signaling in 
development and medulloblastoma.   Toward this goal, first, I aimed to characterize the 
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SmoA2 mouse model of medulloblastoma with hyperactive Shh signaling in the cerebellum. 
Through a comparative study with the SmoA1 model, I investigated if aberrant Shh signaling 
in the cerebellum stemming from different activating mutations have disparate effects on 
development and cancer. The findings from this study are described in Chapter 2. Toward my 
second aim, my finding that muscle differentiation factor, MyoD acts as a haploinsufficient 
tumor suppressor in Shh-driven mouse models of medulloblastoma, is described in Chapter 
3. Finally, I aimed to understand the effect of extrinsic Shh signaling in the tumor 
microenvironment on medulloblastomas that are not caused by aberrant intrinsic Shh 
signaling. My findings are summarized in Chapter 4. 
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Chapter 2 
Oncogenic mutation in Smoothened causes severe cerebellar developmental 
defects and medulloblastoma in mice 
Abstract 
Deregulated developmental processes in the cerebellum cause medulloblastoma, the most 
common malignant tumor of the central nervous system. About 25-30% of cases are caused 
by mutations increasing the activity of the Sonic hedgehog (Shh) pathway, a critical mitogen 
in cerebellar development. The proto-oncogene Smoothened (Smo) is a key transducer of the 
Shh pathway. Activating mutations in Smo that lead to constitutive activity of the Shh 
pathway have been identified in human medulloblastoma. To understand the molecular and 
cellular effects of Smoothened variants in normal development and medulloblastoma genesis, 
we generated the SmoA2 transgenic mouse model that expresses the transgene exclusively in 
granule neuron precursors and carried out a comparative analysis with our previous SmoA1 
model. In this study, we demonstrate how two apparently similar point mutations in Smo can 
produce starkly different phenotypes. The SmoA2 mice have severe aberrations in cerebellar 
development whereas the SmoA1 mice are largely normal during development. 
Medulloblastomas in the SmoA2 mice develop in the dysplastic cerebellar milieu. Despite 
disruptions in the stereotypic organization of the cerebellum, the SmoA2 mice do not exhibit 
any overt abnormalities in motor coordination. The differences in the global transcriptional 
profiles downstream of SmoA2 and SmoA1 further distinguish the two oncogenic Smo 
mutations. The SmoA2 model will enable investigation of the functional significance of the 
reiterative cerebellar circuitry as well as further our understanding of the Shh pathway in 
cerebellar development and oncogenesis. 
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Introduction 
The protracted phase of extensive proliferation during cerebellar development makes 
it vulnerable to neoplastic transformation (Wang and Zoghbi, 2001). Medulloblastoma, a 
developmental cancer of the cerebellum, continues to be the most common pediatric brain 
cancer. Standard treatments result in neurocognitive impairment and adverse quality of life 
(Gilbertson and Ellison, 2008; Saury and Emanuelson, 2011).  
Medulloblastomas are categorized based on histological characteristics and molecular 
signatures (Gilbertson and Ellison, 2008; Taylor et al., 2011). Genetic aberrations leading to 
hyperactive Shh signaling in granule neuron precursors (GNPs) cause 25-30% of 
medulloblastoma cases (Hatten and Roussel, 2011). The Shh pathway plays a pivotal role in 
cerebellar development by regulating proliferation of GNPs and foliation (Wechsler-Reya 
and Scott, 1999; Corrales et al., 2006). The Shh-subgroup has been widely studied with 
numerous mouse models recapitulating the human disease (Markant and Wechsler-Reya, 
2011). The overall prognosis in patients with Shh-driven medulloblastomas, however, 
remains intermediate (Taylor et al., 2011). 
Within the Shh-subgroup of human medulloblastoma there exists significant 
biological and clinical heterogeneity, the underlying molecular basis of which remain to be 
explored (Northcott et al., 2011b; Sengupta et al., 2011). Leptomeningeal dissemination 
observed uniquely in Smo/Smo mice and not other Shh-driven models (Hatton et al., 2008) 
demonstrate disparities in pathology. Inhibition of the Shh pathway by Smo antagonist, 
cyclopamine varies based on mutations driving hyperactive signaling (Berman et al., 2002; 
Chen et al., 2002) leading to differences in therapeutic responses. Aberrations in genes 
outside the Shh pathway also lead to medulloblastomas with Shh-signatures in mice 
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highlighting the widespread interactions of the Shh pathway with other networks (Markant 
and Wechsler-Reya, 2011). In several mouse models, medulloblastoma-prone progenitors 
exit cell cycle and undergo normal neuronal differentiation suggesting that factors in addition 
to initiating mutations contribute to tumorigenesis (Ayrault et al., 2010) and possibly tumor 
heterogeneity.  
While broad molecular classifications are important, it is necessary to investigate the 
unique behavior of each driving mutation since the downstream effects may be distinct. Since 
medulloblastoma results from developmental aberrations (Marino, 2005), investigation of 
critical milestones in cerebellar development will provide valuable insights in this area. 
Toward this goal, we developed the SmoA2 mouse model of medulloblastoma and carried 
out a comparative analysis with the existing SmoA1 model. SmoA1 (W539L) and SmoA2 
(S537N) mutations, originally identified in human cancer patients (Reifenberger et al., 1998; 
Xie et al., 1998) lie in the same transmembrane domain of Smo and cause constitutive 
activation of the Shh pathway (Taipale et al., 2000). While the SmoA1 mutation has been 
widely studied, very little is known about SmoA2. 
Through characterization of the SmoA2 model, we show striking differences between 
the SmoA1 and SmoA2 mutations at a molecular and cellular level. While the SmoA1 
mutation leads to medulloblastomas, the SmoA2 mutation causes severe defects in cerebellar 
development and medulloblastoma in adulthood. Early in development, the two mutations 
lead to distinct transcriptional profiles affecting different biological processes. Despite 
disruptions in the cytoarchitecture thought to be critical for cerebellar function, the SmoA2 
mice intriguingly do not display signs of cerebellar malfunction. 
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Results:  
Distinct mutations in the Smoothened receptor have vastly different effects on 
cerebellar development.  
SmoA2 (S537N) and SmoA1 (W539L) are activating point mutations that lead to 
constitutive Shh signaling and were originally identified in human cancer cases of 
medulloblastoma and basal cell carcinoma respectively (Reifenberger et al., 1998; Xie et al., 
1998; Taipale et al., 2000). In our previous studies, we have described the SmoA1 transgenic 
mouse medulloblastoma model which expresses the SmoA1 transgene driven by the GNP-
specific fragment of the NeuroD2 (ND2) promoter causing constitutive Shh signaling 
exclusively in the cerebellum (Hallahan et al., 2004; Hatton et al., 2008) 
  In this study, we have characterized the SmoA2 transgenic mouse model with a 
similarly designed transgene expressing the SmoA2 mutation. Comparative histopathological 
analyses show striking differences in phenotypes - while SmoA1 mice have a largely normal 
development of the cerebellum (Figure 2.1 G-I) similar to wildtype (WT) (Figure 2.1 A-C), 
the SmoA2 mice have severe malformations (Figure 2.1D-F).  
At postnatal day (P) 5, the SmoA2 cerebellum has an extended, undefined external 
granular layer (EGL) consisting of aberrantly migrating GNPs (Figure 2.1D). There is lack of 
normal foliation and ectopic progenitor-like cells in the adjacent parenchyma and along the 
pial surface (Figure 2.1D). At P14, the SmoA2 cerebellum continues to manifest extensive 
dysplasia with massive hypercellularity (Figure 2.1E). The dysplastic regions consist of 
normal progenitor cells and atypical cuboidal to spindle-shaped cells with indistinct cell 
borders, scant amount of eosinophilic fibrillar cytoplasm with irregularly round to fusiform 
nuclei, reminiscent of medulloblastoma. These features strongly suggest a primitive 
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phenotype and possible neoplastic transformation. However, the atypical cells in the SmoA2 
P14 cerebellum also have morphological similarities to the normal GNPs remaining in the 
outer EGL of the WT P14 cerebellum that are still undergoing migration.  
By P28, the WT cerebellum attains its mature size and shape (Figure 2.1C). Although 
a 100% of the SmoA2 cerebella remain dysplastic in adult mice, the cytoarchitecture is more 
mature compared to the hypercellular P14 stage (Figure 2.1F). The cells in the dysplasia are 
morphologically identical to the mature granule neurons in the WT cerebellum. At this stage, 
atypical cells if any, are exclusively positioned along the pial surface, clearly separate from 
the adjacent dysplastic regions. 
To ensure that the phenotype observed is caused by the specific SmoA2 mutation and 
not consequent to disruptions caused by transgene integration, we analyzed two independent 
transgenic lines (221, 225). Both lines displayed cerebellar malformations, confirming that 
the phenotype observed stems from the SmoA2 mutation (Figure 2.1 J,K).  
 
Medulloblastoma in the SmoA2 model develop in a dysplastic milieu 
GNPs in the proliferative EGL are known to be the source of medulloblastomas 
caused by hyperactive Shh signaling (Goodrich et al., 1997; Oliver et al., 2005; Hatton et al., 
2008; Schuller et al., 2008; Yang et al., 2008). The SmoA2 mice, as shown earlier, lack an 
organized EGL and the entire laminar cytoarchitecture of the cerebellum remains dysplastic 
throughout development (Figure 2.1 D-F). To understand the nature of tumor formation in 
these mice, we carried out a comparative histopathological analyses on SmoA2 and SmoA1 
tumors. The histological criteria we used for tumor definition were the same as those 
established in our previous study (Hatton et al., 2008). Further to our initial report of  
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Figure 2.1 | The SmoA1 and SmoA2 mutations have vastly different effects on the development of mouse cerebellum. 
Hematoxylin-Eosin (H&E) staining of representative sagittal sections show development of the mouse cerebellum at P5, 
P14 and P28 in (A-C) WT, (D-F) SmoA2 and (G-I) SmoA1 mice. (A-C) Asterisks indicate fissure formation during foliation 
at P5 and dotted arrow denotes the anteroposterior (A-P) axis. At P14, formation of the molecular layer, Purkinje cell (PC) 
layer, Internal granular layer (IGL) near completion with remnants of the External granular layer (EGL) (arrow). At P28, the 
mature cerebellum is fully formed. (D-F) The SmoA2 cerebellum has an ill-defined expanded EGL with loss of foliation. 
Arrows point to ectopic clusters of cells at P5 and P14. In the P28 adult SmoA2 cerebellum, atypical cells with neoplastic 
morphology, if any, are concentrated along the superficial surface separated from the dysplastic region (dotted line). (G-I) 
The SmoA1 cerebellum closely parallels the development of the WT cerebellum except for a slight thickening of the EGL at 
P14 (H; arrows). In the P28 adult SmoA1 cerebellum, neoplastic cells, if any, localize to the superficial surface of the 
cerebellum (I; arrows). Insets in (A, D, G) show high magnification views of EGL and PC layers at P5, inset in (E) shows a 
mix of atypical and normal cells at P14 and inset in (F) shows concentration of atypical cells along the superficial surface. 
(J-K) H&E staining of horizontal sections from two independent SmoA2 transgenic lines 221 and 225 show disrupted 
cerebellar cytoarchitecture in adult mice from both lines (age > 2 months). Scale bars (A-K) 500µm, insets 25µm 
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hyperplasia in the SmoA2 line, our subsequent experiments reveal tumorigenesis (Hallahan 
et al., 2004).  
The SmoA2 mice develop cerebellar tumors in a dysplastic cerebellar milieu (Figure 
2.2A) compared to the SmoA1 tumors which form in an otherwise normally developed 
cerebellum (Figure 2.2D) and are preceded by an expansion of the EGL at P14 (Hatton et al., 
2008) (Figure 2.1H). The frank solid tumors are densely cellular with oval to spindle shaped 
cells (Figure 2.2B, F) arranged in undefined sheets, short streams and bundles supported on a 
scant fibrovascular stroma. Multifocally, neoplastic cells palisade along vessels and form 
numerous pseudorosettes. Although during development the entire SmoA2 cerebellum 
appears hypercellular with atypical cells and other features of neoplasia (Figure 2.2D-F), 
even in the absence of a defined EGL, the solid tumors are localized in anatomic regions 
along the pial surface (Fig 2.2A).  
A natural history study to determine the clinical incidence of tumor formation in the 
SmoA2 mice (n=235) show 2% of the SmoA2 mice manifest clinical symptoms of tumor 
formation at 2 months of age, which increases to 46% by 4 months and 76% by 6 months 
(Figure 2.2G) similar to the SmoA1 model (Hatton et al., 2008). The main clinical 
symptoms, as previously described (Hatton et al., 2008) were weight loss, protruded head as 
a result of tumor formation beneath the skull, hunched posture or head tilt resulting from 
hydrocephalus or nerve impingement, and lethargy. Histological analyses using 
asymptomatic SmoA2 mice show 80% of the SmoA2 mice (n=15) have subclinical 
neoplastic lesions by 2 months, which increases to 100% by 4 months of age (n=16).  
The presence of neoplastic features as early as P5 indicated that the SmoA2 mutation 
confers transformative potential to precursor cells early in development much before the  
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Figure 2.2 
Comparative histopathology of SmoA2 and SmoA1 medulloblastomas  
(A) Representative images from horizontal cerebellar sections show formation of SmoA2 tumors (arrow) in an aberrantly 
developed cerebellum on the superficial surface, m denotes meninges. (B) pleomorphic neoplastic cells with multifocal 
pseudorossettes are distinct from (C) uniformly round granule neurons (GN) and Purkinje cells (PC) in adjacent dysplasia. 
(D) SmoA1 tumors (arrow) form adjacent to a normally developed cerebellum also along the superficial surface. (E) Normal 
cellular morphology is distinct from (F) adjacent tumor cells. (G) Columns represent cumulative tumor incidence in SmoA2 
and SmoA1 (Hatton et al., 2008) mice at 2, 4 and 6 months of age, based on manifestation of clinical symptoms. (H) Highly 
vascularized allograft tumor in athymic recipient mice (n=5) transplanted orthotopically with granule neuron precursor 
(GNP)-enriched cells from P5 SmoA2 donor mice. Scale bars (A-F, H) 100µm 
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onset of clinical disease. To investigate the oncogenic potential of SmoA2 precursors, we 
transplanted GNP-enriched cells isolated from P5 SmoA2 cerebella, orthotopically into 
immunocompromised recipient mice. All five recipients succumbed to aggressive tumors 
between 20-30 days after transplantation (Figure 2.2H) confirming that the SmoA2 
expressing GNPs have neoplastic properties and lead to aggressive tumorigenesis. The 
simultaneous manifestation of cerebellar developmental defects as well as neoplastic changes 
as early as P5 in the SmoA2 mice makes this a powerful model to study the temporal 
progression of an embryonal tumor like medulloblastoma.  
 
The SmoA2 mutation independently increases neuronal proliferation and affects 
neuronal migration in the cerebellum.  
The Shh signaling pathway plays a crucial role in proliferation of GNPs by acting as a 
mitogen during postnatal cerebellar development (Wechsler-Reya and Scott, 1999). We 
therefore characterized the proliferative status of the SmoA2 cerebellum at different 
developmental stages. The first developmental stage we investigated was embryonic day 
(E)15.5 since the EGL consisting of proliferating GNPs is formed by this stage (Ben-Arie et 
al., 1997) and the ND2 promoter driving the SmoA2 transgene is activated at ~ E11 (Lin et 
al., 2004). Immunohistochemical (IHC) staining for proliferation marker, Ki67 shows an 
increased number of proliferating progenitors in the expanded EGL, compared to WT 
controls (Figure 2.3A, B). This feature is maintained at P5 with disorganized proliferating 
cells, which persist at P14 in SmoA2 mice (Figure 2.3F, G) as opposed to WT where 
proliferation is high at P5 but nearly complete by P14 (Figure 2.3C, D). In the P28 SmoA2 
cerebellum, the Ki67 positive cells remain in the outer surface of the cerebellum in the same 
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Figure 2.3 
The SmoA2 mutation has independent effects on neuronal proliferation and neuronal and glial organization (A-B) 
Ki67 immunohistochemistry (IHC) identifying proliferating GNPs marks the EGL (white arrow), which is expanded in 
SmoA2 mice compared to WT at embryonic day (E)15.5. IHC analysis for Ki67 in (C-E) WT cerebella at P5, P14 and P28 
compared to that in (F-H) SmoA2 shows disorganized regions of proliferating GNPs (arrows) in SmoA2 at P5 compared to 
the defined EGL in WT. At P14, while a few proliferating cells remain in the outer EGL (arrow) in WT, there is an 
abundance of proliferating GNPs in SmoA2. At P28 proliferation is complete in WT whereas Ki67-positive cells are present 
along the superficial surface of the SmoA2 cerebellum. (I) SmoA2 tumors have an abundance of Ki67-positive cells, which 
are (J) undetectable in the dysplastic regions of the SmoA2 cerebella. (K-M) H&E staining of representative sagittal 
cerebellar sections show that while the EGL is expanded in both PtchF/F-Math1-Cre and SmoA2 models, mechanisms 
underlying foliation and neuronal migration to form the laminar cytoarchitecture are preserved in the former as opposed to 
the SmoA2 cerebellum. n=3 per group. Scale bar: (A-M) 100µm 
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region (Fig 2.3H) where the atypical cells are localized, as shown in Figure 2.1F. There are 
no Ki67-positive cells in the P28 WT cerebellum (Figure 2.3E). The SmoA2 tumors have 
extensive Ki67 staining compared to the dysplastic regions where Ki67 is undetectable 
(Figure 2.3 I, J).  
Next we investigated whether the abnormal foliation and migration observed in the 
SmoA2 cerebellum is a consequence of excess GNPs generated from Shh hypersignaling that 
could potentially overwhelm and deregulate cell migration processes. To address this, we 
compared the P5 cerebella of the SmoA2 mice to an additional Shh-driven medulloblastoma 
model, the Patched conditional knock-out mice (PtchF/F Math1-Cre) (Yang et al., 2008) 
(Figure 2.3K, L, M). At P5, the PtchF/F Math1-Cre mice have a vastly increased number of 
GNPs. However, neuronal migration to form the laminar architecture and mechanisms 
underlying foliation appear to be preserved (Figure 2.3L). This shows that the neuronal 
disorganization in the SmoA2 cerebellum is not solely a consequence of uncontrolled GNP 
proliferation. 
 
SmoA2 mutation causes aberrations in neuronal and glial organization 
To investigate the cellular characteristics of the cerebellar dysplasias observed in the SmoA2 
mice, we identified granule neurons and Purkinje cells as well as Bergmann glia that are 
critical in GNP migration using antibodies for NeuN, Calbindin and S100 respectively. By 
immunohistochemical techniques, we analyzed three distinct stages of cerebellar 
development namely P5, P14, and P28 as well as SmoA2 tumors and non-tumor cerebellar 
dysplasia in adult mice. All three markers showed massive disruptions in the organization of 
granule neurons, Purkinje cells and radial glia in the SmoA2 mice (Figure 2.4 D-F, J-L, P-R)  
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Figure 2.4 
SmoA2-induced aberrations in neuronal and glial organization in the developing cerebellum  
NeuN IHC analysis at P5, P14 and P28 developmental stages comparing (A-C) WT cerebella to (D-F) SmoA2 cerebella, 
show disorganized clusters of differentiated granule neurons (GN) amidst abundant NeuN negative cells at P5 and P14 in 
SmoA2. Calbindin IHC for Purkinje cells (PC) show, monolayer organization in (G-I) WT and (J-L) ectopic clusters in 
SmoA2 with disorganized dendritic arbors and axonal collaterals at P5, P14 and P28. (M-R) S100 IHC analysis for radial 
glia comparing (M-O) WT cerebella to (P-R) SmoA2, shows disorganized, entangled glial processes in the SmoA2 
cerebellum at P5, P14 and P28. (S-U) SmoA2 tumors show heterogeneous NeuN staining, absence of PCs and 
heterogeneous S100 staining whereas (V-X) adjacent dysplasias are composed of mature but disorganized GNs, PCs and 
radial glia. n=3 per group. Scale Bar: (A-X) 100µm 
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compared to the WT littermate controls (Figure 2.4 A-C, G-I, M-0).  
At P5, the SmoA2 cerebellum has an ill-defined outer region negative for NeuN and 
an inner region of NeuN positive mature neurons similar to the forming Internal granular 
layer (IGL) of the WT cerebellum (Figure 2.4A, D). At P14, in the SmoA2 cerebellum there 
are clusters of NeuN positive neurons marking islands of differentiated cells amidst a vast 
expanse of NeuN negative cells (Figure 2.4E) in stark contrast to the WT cerebellum where 
differentiated NeuN positive cells are located in the near complete IGL at this stage (Figure 
2.4B). At P28, in SmoA2, majority of the neurons are NeuN positive representing a 
differentiated state with clusters of NeuN negative cells toward the outer surface of the 
cerebellum (Figure 2.4F), the same region where clusters of Ki67 positive proliferating cells 
are observed (Figure 2.3H). 
Calbindin immunostaining shows that the Purkinje cells have severely disorganized 
dendritic arbors and axonal processes in the SmoA2 cerebella and the cell bodies fail to align 
in the characteristic monolayer array at all the developmental stages analyzed (Figure 2.4J-L) 
in comparison to WT controls (Figure 2.4 G-I). Compared to the WT controls (Figure 2.4 M-
O), S100 staining of the radial glia show atypical glial tangles with entrapped granule 
neurons in ectopic locations in the SmoA2 mice (Figure 2.4P-R).  
The SmoA2 tumors show a heterogeneous pattern of NeuN staining (Figure 2.4S); 
absence of Calbindin positive-Purkinje cells (Figure 2.4T) and sparse to absent S100-positive 
glia (Figure 2.4U). The SmoA2 adult dysplasias on the other hand consist of NeuN-positive 
neuronal cells (Figure 2.4V). The dysplastic regions also consist of disorganized Purkinje 
cells (Figure 2.4W) and disorganized glial fibrils (Figure 2.4X). These results demonstrate 
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that the GNP-specific expression of SmoA2 leads to widespread disruptions in migration and 
organization of other neuronal and glial cell types in the cerebellum. 
 
Severe defects in cerebellar morphology do not cause overt anomalies in motor 
coordination in SmoA2 mice 
The classic functions of the cerebellum which are regulation of balance and motor 
coordination are thought to be dependent on its organized laminar cytoarchitecture (Ghez, 
1985). The granule neurons carry sensory inputs to the cerebellum while the Purkinje cells 
are the primary motor output from the cerebellum relaying motor information to higher brain 
centers. To assess potential abnormalities in motor coordination resulting from 
neuroanatomic defects of the SmoA2 cerebellum, we used a modified neurobehavioral 
assessment tool based on SHIRPA (Rogers et al., 1997) (see materials and methods for 
details). We investigated physical phenotype (weight, tremor, body position and tail position) 
and behavioral phenotype (grooming, locomotor activity, spontaneous motor activity). 
Additionally, we conducted the accelerated rotarod assay to test fore and hind limb 
coordination and balance) in both adult SmoA2 and age-matched WT control mice. No 
differences in physical phenotype were observed and except for a decrease in locomotor 
activity (p <0.01), there were no significant differences in behavior phenotype measures 
between WT and SmoA2 mice (Table 2.1). Importantly, there was no difference in rotarod 
performance between SmoA2 and WT demonstrating that these mice were not deficient in 
motor coordination and balance. We also conducted a footprint analysis using stride length 
and stance width measures (Crawley, 1999) in both SmoA2 and WT mice which 
demonstrated no evidence of ataxic gait, a common consequence of cerebellar dysfunction  
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Table 2.1: Measures from Neurobehavioral Assessment 
 
Test 
 
 
Measure 
WT SmoA2 
N Mean SEM N Mean SEM 
Rotarod Latency to fall 
(secs) 
 
8 222.4 1.04 12 189.8 0.59 
 
Footprint 
Analysis 
Stride length (cm) 
 
3 63.2 3.84 4 60.4 2.13 
Stance width (cm) 
 
3 22.5 0.64 4 23.3 1.03 
*Locomotor 
activity 
*p value < 0.01 
 
Number of times 
the mouse places 
at least one paw 
on the side of the 
cage during a 2-
minute 
assessment 
8 12.1 0.07 12 6.5 0.02 
 
Table 2.1 Legend 
Table 2.1 shows measures (mean) obtained from accelerated rotarod test, footprint analysis and locomotor activity as part of 
SHIRPA assessment to assess neurobehavior of SmoA2 mice with respect to age-matched WT control mice (age > 2 
months). N denotes the number of mice in each group. Except for a decrease in locomotor activity (p value < 0.01) in 
SmoA2 mice, there is no significant difference in any other measure between SmoA2 and WT mice. 
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(Table 2.1). Together, these data reveal no overt abnormalities in cerebellar function in 
SmoA2 mice despite massive disorganization in the cytoarchitecture. 
 
SmoA2 and SmoA1 mutations lead to unique transcriptional profiles in the mouse 
cerebellum 
To investigate whether the SmoA2 and SmoA1 mutations differentially activate the 
Shh pathway in vivo, we assessed mRNA levels of the canonical target genes by quantitative 
reverse transcription (qRT)-PCR in SmoA2 and SmoA1 P5 cerebella (Figure 2.5A). Except 
for total Smo expression (endogenous and transgene), which is 2.8 fold higher in SmoA2 
compared to SmoA1, expressions of the remaining targets are not significantly different 
between SmoA2, SmoA1 and WT P5 mice. The extent of Shh pathway activation is similar 
because at P5, this pathway is highly active in both WT and the Smo mutants when the GNPs 
are in the maximal proliferative phase. At later stages, as expected, the levels of these targets 
are elevated in SmoA2 and SmoA1 cerebella (data not shown). 
Next, to assess transcriptional changes downstream of SmoA2 and SmoA1, we 
evaluated global gene expression profiles of P5 SmoA2, SmoA1 and WT age-matched 
cerebella. We chose this specific developmental stage because (1) the phenotypes of SmoA2 
and SmoA1 are robust and distinct at P5; (2) at P5 GNPs undergo proliferation, migration 
and differentiation and therefore expression profiling could capture key differences in 
multiple processes. Hierarchical cluster analysis shows that while the gene expression 
signature is unique for each group, at P5, transcriptionally the WT and SmoA1 cerebella 
resemble each other more closely than either resembles SmoA2 (Figure 2.5B), consistent 
with their phenotypes (Figure 2.1 A, D, G). 
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Compared to WT controls, we identified 106 transcripts in SmoA2 and 67 in SmoA1 
that differed uniquely by an absolute fold change of greater than or equal to 2, p < 0.001 
(Figure 2.5C). This highlights the complex transcriptional changes induced by the SmoA2 
mutation that potentially underlie the intriguing phenotype.  
To determine key biological processes that are different between SmoA2 and SmoA1, 
we used mRNAs over- and under-represented in SmoA2 compared to SmoA1 to conduct 
Gene Ontology (GO) gene set enrichment analyses (Ashburner et al., 2000). The ontological 
categories represented by the gene sets up- or down-regulated in SmoA2 compared to 
SmoA1 include cell and neuronal fate specification and commitment, regulation of neuronal 
differentiation, neural crest cell migration, regulation of cell proliferation, neuron migration, 
neuronal projection, membrane anchorage, cell matrix adhesion, axonal and dendritic 
molecules, localization molecules, ligand gated ion channel activity, thyroid hormone 
metabolism as well as various metabolic processes amongst others. In the cell fate 
commitment GO category, among other transcription factors, the expression of MyoD, a 
transcription factor that orchestrates muscle differentiation, was particularly intriguing since 
MyoD is neither known to be expressed nor have a function in the mammalian brain. qRT-
PCR as well as Western blot analysis (data not shown) confirmed this ectopic expression 
pattern. We are currently exploring the significance of this unexpected finding. In summary, 
the biological processes reflected by the gene expression profiles are complex and 
ascertaining specific pathways remains a future direction. Our data demonstrate the 
fundamental differences between SmoA2 and SmoA1 at a molecular level that affect distinct 
biological processes. 
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Figure 2.5 
Transcriptional profiles of SmoA1 and SmoA2 P5 cerebella 
(A)!mRNA!expression!of!canonical!Shh!target!genes!Gli1,&Gli2,&Ptch1,&Ptch2&and&Smo&(endogenous!+!transgene!expression)!as!determined!by!qRTJPCR!analysis!using!mRNA!from!WT,!SmoA2!or!SmoA1!P5!cerebella!(n=3!per!genotype).!Columns!represent!average!foldJchange!of!each!target!in!SmoA2!and!SmoA1!relative!to!WT!controls.!
Gapdh!was!used!as!the!endogenous!control.!Each!condition!was!run!in!triplicate.!Total!Smo!expression,!2.8Jfold!higher!in!SmoA2!compared!to!SmoA1,!is!the!only!target!whose!difference!was!statistically!significant!(Student!tJtest;!
p!value!<0.01).!Error!bars!represent!+!SEM!(B)!Hierarchical!cluster!analysis!shows!transcriptional!similarity!of!WT!and!SmoA1!P5!cerebella!in!comparison!to!SmoA2!(n=3!per!genotype)!(C)!Venn!diagram!shows!unique!and!overlapping!changes!in!transcript!expression!(>!2!absolute!fold!change,!p<0.001)!between!P5!SmoA2!and!SmoA1!cerebella.!!!!!!
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Table 2.2 Genes uniquely up-regulated in the postnatal day 5 SmoA2 cerebella compared to 
age-matched WT controls 
 
Accession Number Gene symbol    *Fold change   
 
NM_145745 Adam34 5.5 
 NM_138944 Pou4f2 5.2 
 NM_026358 4930583H14Rik 4.7 
 NM_011143 Pou4f1 4.4 
 NM_011314 Saa2 4.3 
 NM_010866 MyoD 4 
 NM_021399 Bcl11b 3.8 
 NM_175631 Cbln4 3.7 
 AK047003 Herc1 3.5 
 ENSMUST00000067450 2700046A07Rik 3.4 
 AK141295 Sema3e 3.4 
 ENSMUST00000066060 Bcl11b 3 
 BB367552 Bcl11b 3 
 AK035897 Ranbp17 2.8 
 AK081638 None 2.7 
 NM_029530 6330527O06Rik 2.7 
 NM_181529 Syt15 2.6 
 AK050850 Igf2bp1 2.6 
 NM_001007584 OTTMUSG00000002038 2.5 
 NM_009951 Igf2bp1 2.5 
 NM_009144 Sfrp2 2.4 
 NM_009236 Sox18 2.4 
 ENSMUST00000066047 Bcl11b 2.3 
 NM_007662 Cdh15 2.3 
 NM_007606 Car3 2.2 
 ENSMUST00000035914 BC034090 2.2 
 AF017639 Cpxm2 2.2 
 NM_145497 BC016495 2.2 
 NM_007555 Bmp5 2.1 
 NM_023146 Ranbp17 2.1 
 AK030810 Cdk6 2.1 
 NM_172485 Thsd7b 2.1 
 NM_001045514 Akna 2 
 AK036025 None 2 
 NM_011923 Angptl2 2 
 AV290704 Angptl2 2 
 NM_009625 Adcyap1 2 
 NM_130858 Nxph3 2 
 
! 41!
Table 2.2 continued 
Accession Number Gene symbol    *Fold change   
_________________________________________________________________________ 
*Absolute Fold changes > 2 are shown in this table.       
Positive numbers mean increase in expression and negative numbers mean reduction in expression compared to 
age-matched WT controls (pooled)     
All genes meet the p < 0.01 level of significance       
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
NM_145463 Shisa2 1.9 
AK029182 None 1.9 
AK020918 A930032L01Rik 1.9 
NM_013820 Hk2 1.9 
AK160412 Bmp5 1.9 
CD562285 Car2 1.9 
NM_008958 Ptch2 1.9 
NM_139134 Chodl 1.9 
ENSMUST00000074819 2410127L17Rik 1.9 
NM_026929 Chac1 1.9 
AK144315 Epb4.1l4b 1.9 
AK027955 1110034N17Rik 1.9 
NM_026929 Chac1 1.9 
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Table 2.3 Genes uniquely down-regulated in the postnatal day 5 SmoA2 cerebella compared 
to age-matched WT controls 
 
Accession Number Gene symbol    *Fold change   
 
NM_175647 Dmrta1 -4.3 
 CA323388 Sypl2 -3.3 
 NM_009022 Aldh1a2 -3 
 NM_146010 Tspan8 -2.9 
 NM_153565 Pcsk9 -2.9 
 DQ656357 D0Kist2 -2.8 
 BC030038 Sypl2 -2.7 
 NM_008766 Slc22a6 -2.7 
 BC069182 Trp73 -2.7 
 NM_173375 BC064033 -2.6 
 NM_018857 Msln -2.6 
 NM_172709 Otop1 -2.5 
 ENSMUST00000039303 Npy1r -2.4 
 NM_009864 Cdh1 -2.3 
 NM_011915 Wif1 -2.3 
 NM_010277 Gfap -2.3 
 NM_181588 Cmbl -2.2 
 NM_133661 Slc6a12 -2.2 
 NM_133229 Ripply3 -2.2 
 NM_013519 Foxc2 -2.2 
 AK039668 A730046J19Rik -2.1 
 NM_148933 Slco4a1 -2.1 
 NM_144512 Slc6a13 -2.1 
 BC066851 Pcdhga12 -2.1 
 NM_007553 Bmp2 -2.1 
 NM_009714 Asgr1 -2.1 
 NM_007501 Neurod4 -2 
 NM_001010937 Gjb6 -2 
 NM_011153 None -2 
 NM_008963 Ptgds -2 
 NM_175012 Grp -2 
 NM_007494 Ass1 -2 
 ENSMUST00000095183 Nrxn1 -2 
 NM_172870 Bnc2 -2 
 NM_021355 Fmod -1.9 
 BC038653 Lyve1 -1.9 
 ENSMUST00000058077 E030011K20Rik -1.9 
 NM_011324 Scnn1a -1.9 
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Table 2.3 continued 
 
Accession Number Gene symbol    *Fold change   
 
NM_172446 Lbxcor1 -1.9 
AK032623 A930035E12Rik -1.9 
C78942 D1Ertd218e -1.9 
AK049102 A830029E22Rik -1.9 
NM_183183 Gprin3 -1.9 
AK036173 None -1.9 
ENSMUST00000068175 Gm941 -1.9 
AK047689 None -1.9 
NM_001024139 Adamts15 -1.9 
AK081659 C130061O14Rik -1.9 
NM_146241 Trhde -1.9 
ENSMUST00000000031 None -1.9 
NM_172399 A930038C07Rik -1.9 
NM_008471 Krt19 -1.9 
NM_010701 Lect1 -1.9 
AK136780 Gm626 -1.9 
_________________________________________________________________________ 
 
* Absolute Fold changes (FC) > 2 are shown in this table (p value < 0.001)     
Fold changes expressed in negative numbers denote reduction in expression compared to age-matched WT 
controls (pooled)     
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Table 2.4 Genes uniquely up-regulated in the postnatal day 5 SmoA1 cerebella compared to 
age-matched WT controls 
 
Accession Number Gene symbol    *Fold change   
 
NM_013496 Crabp1 11.5 
 NM_001013767 Capn11 4.9 
 AY540025 Mid1 4.1 
 ENSMUST00000011398 Thg1l 3.9 
 NM_139225 Defb10 3.4 
 XM_907202 Ccnb1ip1 3.3 
 NM_011436 Sorl1 3.3 
 NM_012011 Eif2s3y 3 
 NM_139219 Defb9 2.9 
 BC030050 621998 2.8 
 NM_207229 Plac9 2.7 
 NM_013823 Kl 2.6 
 BC085191 Diap3 2.6 
 AK049248 Slc4a5 2.3 
 NM_007739 Col8a1 2.3 
 NM_053181 Pdxdc1 2.3 
 NM_001080969 Thg1l 2.3 
 NM_026323 Wfdc2 2.2 
 NM_183389 Duxbl 2.2 
 ENSMUST00000054217 Wfikkn2 2.2 
 NM_021395 Hyou1 2.2 
 NM_025311 D14Ertd449e 2.2 
 CJ298892 AI317185 2.2 
 AK018742 Col8a1 2.1 
 NM_178446 Rbm47 2.1 
 NM_008312 Htr2c 2.1 
 ENSMUST00000034998 4930422I07Rik 2.1 
 AK018220 6330525I24Rik 2 
 AK160781 Plac9 2 
 AK133500 Comt1 2 
 AK152971 Rbm47 2 
 AK009210 2310007J06Rik 2 
 AK034789 5830458C19Rik 1.9 
 NM_199473 Col8a2 1.9 
 AK013119 Rcbtb2 1.9 
 AI987986 D14Ertd449e 1.9 
 AK083103 Mobp 1.9 
 NM_001009935 Txnip 1.9 
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Table 2.5 Genes uniquely down-regulated in the postnatal day 5 SmoA1 cerebella compared 
to age-matched WT controls 
 
Accession Number Gene symbol    *Fold change   
__________________________________________________________________________ 
 
* Absolute Fold changes (FC) > 2 are shown in this table (p value < 0.001)     
Fold changes expressed in negative numbers denote reduction in expression compared to age-matched WT 
controls (pooled)        
 
 
 
 
NM_009209 Slc6a2 -7.4 
 NM_009431 Ctr9 -5.7 
 NM_008623 Mpz -5.6 
 AK084170 D230004N17Rik -4.8 
 AK159710 Wdfy1 -4.2 
 NM_175498 Pnma2 -4 
 NM_028121 Adpgk -3.9 
 AK158527 None -3.7 
 AK043426 A730094K22Rik -3.4 
 AK034149 9330159M07Rik -3.2 
 NM_001039533 Pdxdc1 -3.1 
 AK046789 B830008M09Rik -3 
 AK042670 A730014G21Rik -2.9 
 AK011224 Rbm3 -2.9 
 AK048966 C230086J09Rik -2.9 
 AK050253 9430037G07Rik -2.8 
 AK142900 None -2.7 
 AK165554 Wdfy1 -2.6 
 AK142214 EG666451 -2.6 
 NM_016809 Rbm3 -2.6 
 DT932411 None -2.3 
 BC058551 Il6st -2.2 
 AK014787 4833428M15Rik -2.1 
 NM_013603 Mt3 -2.1 
 XM_001006405 None -2.1 
 NM_023831 1500035H01Rik -2.1 
 NM_020279 Ccl28 -2 
 AK013947 Gmfb -1.9 
 NM_001039198 Zfhx2 -1.9 
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Table 2.6 Genes up-regulated in both postnatal day 5 SmoA2 and SmoA1 cerebella 
compared to age-matched WT controls 
 
Accession Number Gene symbol SmoA2  FC SmoA1 FC 
 
NM_021459 Isl1 8.5 2.4 
NM_183173 Ankrd43 6.5 3 
NM_010446 Foxa2 6.1 3 
AK011210 2600014E21Rik 3.5 1.8 
NM_001081171 Lama5 3.5 1.7 
NM_001081127 Adamts14 3.3 1.6 
AK021003 B230216N24Rik 3.2 1.5 
NM_012008 Ddx3y 3.1 3.5 
AK013627 2900040C04Rik 2.9 4 
NM_016675 Cldn2 2.8 2.6 
NM_139221 Defb11 2.7 3.5 
NM_008034 Folr1 2.6 3.1 
NM_016674 Cldn1 2.5 3.1 
NM_011545 Tcf21 2.5 2.8 
NM_172469 Clic6 2.4 3.2 
NM_001035245 Trpm3 2.4 2.8 
ENSMUST00000040002 1110059M19Rik 2.3 3.2 
NM_134110 Kcne2 2.3 3.1 
NM_001035246 Trpm3 2.3 2.4 
NM_001017407 1700021K02Rik 2.3 1.6 
NM_007472 Aqp1 2.2 3.3 
AY134666 Sostdc1 2.2 2.8 
NM_178768 Tmem72 2.2 2.6 
ENSMUST00000099699 4631405J19Rik 2.2 1.5 
NM_178406 Gpr153 2.2 1.3 
NM_013697 Ttr 2.1 2.5 
AK166311 Cdk6 2.1 1.3 
NM_178396 Car12 2 2.5 
NM_027399 Steap1 2 2.4 
BC060172 Ccnd1 2 1.6 
ENSMUST00000025631 Ostf1 2 1.5 
NM_177152 Lrig3 2 1.3 
AK013544 2900017F05Rik 1.9 2.2 
NM_024283 1500015O10Rik 1.9 2 
NM_007378 Abca4 1.9 1.9 
AK164997 Ccnd1 1.9 1.5 
AK076778 4930447K04Rik 1.9 1.4 
BC057642 2010011I20Rik 1.9 1.4 
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Table 2.6 continued 
 
Accession Number Gene symbol SmoA2  FC SmoA1 FC 
 
AK154197 Cdk6 1.9 1.3 
NM_010664 Krt18 1.8 2.5 
NM_138304 Calml4 1.6 2.5 
__________________________________________________________________________ 
 
* Absolute Fold changes (FC) > 2 are shown in this table (p value < 0.001)     
Fold changes expressed in negative numbers denote reduction in expression compared to age-matched WT 
controls (pooled)       
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Table 2.7 Genes down-regulated in both postnatal day 5 SmoA2 and SmoA1 cerebella 
compared to age-matched WT controls 
 
Accession Number Gene symbol SmoA2  FC SmoA1 FC 
 
NM_010930 Nov -2.8 -1.7 
NM_026183 Slc47a1 -2.5 -1.8 
ENSMUST00000040960 Slc6a20a -2.2 -1.3 
ENSMUST00000067444 Gfap -2 -1.4 
 
__________________________________________________________________________ 
 
* Absolute Fold changes (FC) > 2 are shown in this table (p value < 0.001)     
Fold changes expressed in negative numbers denote reduction in expression compared to age-matched WT 
controls (pooled)        
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Discussion 
In this study, we have established a mouse model of medulloblastoma that manifests severe 
defects in critical pathways of cerebellar development including neuronal proliferation, 
differentiation and migration stemming from an activating mutation, SmoA2. Our 
comparative analysis reveals vastly different phenotypic effects of the SmoA2 and SmoA1 
mutations and thereby demonstrates the complexity of the downstream molecular pathways 
regulated by a single molecule. The lack of a significant difference in the level of activation 
of the Shh pathway at P5 suggests that the phenotypic differences are not exclusively due to 
extent of pathway activation. The similarity in global transcriptional profiles between the WT 
and SmoA1 mice in early development is in concurrence with phenotype of SmoA1 being 
indistinguishable from WT at that stage whereas the SmoA2 phenotype and transcriptional 
profile stand unique. We have demonstrated how two activating mutations in an identical 
domain of a single protein can cause unique changes. Identifying molecular pathways 
uniquely employed by SmoA2 and SmoA1 variants with cues from the GO classification 
remains an important future direction that may provide further insights into the mechanics of 
the Shh pathway both in normal development and tumorigenesis.     
The cell of origin of the Shh-driven subtype of medulloblastomas has been shown to belong 
to the granule neuron lineage (Goodrich et al., 1997; Hallahan et al., 2004; Oliver et al., 
2005; Gilbertson and Ellison, 2008; Hatton et al., 2008; Schuller et al., 2008; Yang et al., 
2008). However, why the niche of the superficial surface of the cerebellum is conducive to 
tumorigenesis as seen in several mouse models (Oliver et al., 2005; Hatton et al., 2008; Yang 
et al., 2008) including SmoA2, is yet to be understood. In the Patched heterozygous model 
(Oliver et al., 2005), ectopic rests of pre-neoplastic cells that have failed to undergo proper 
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migration reside in the niche of the EGL whereas the vast majority of GNPs mature and 
organize correctly. Intriguingly, in the SmoA2 developing cerebellum the vast majority of 
GNPs undergo abnormal migration and manifest neoplastic features early in development. 
However, the frank tumors remain confined to the superficial surface of the cerebellum. By 
design of the transgene, each GNP should express the SmoA2 oncogenic mutation, yet 
dysplasias adjacent to the tumors consist of normally differentiated granule neurons. This 
suggests that potential cell-extrinsic factors in the pial surface might act on a subset of 
SmoA2 cells arrested in migration leading to tumor initiation. The cells that have migrated 
away from the EGL differentiate or regress. Alternatively, cell-extrinsic factors could attract 
neoplastic cells to the pial surface by providing a favorable environment for tumor growth. 
The leptomeningeal membrane known to secrete chemokines and other trophic factors 
(Stylianopoulou et al., 1988; Klein et al., 2001), is one potential source of such extrinsic 
signals. Future experiments to further characterize the environmental niche and the residing 
precursors will provide further insights into the development of this subtype of 
medulloblastoma.  
An interesting phenomenon observed in the SmoA2 developing cerebellum is the apparent 
regression of the hypercellularity observed throughout the developing cerebellum. Progenitor 
cells in the developing cerebellum appear to have neoplastic characteristics morphologically 
as well as functionally as shown by transplantation experiments. Yet, in a mature SmoA2 
cerebellum, the dysplasias histologically seem to have fewer cells and consist of mature 
neurons. The early neoplastic lesions are confined to the superficial surface of the cerebellum 
while the rest of the cerebellum remains dysplastic. Spontaneous regression has been 
documented in certain cancers such as the highly malignant Stage 1V-S neuroblastoma 
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(D'Angio et al., 1971; Nickerson et al., 2000) the molecular basis of which is poorly 
understood. There is conflicting data regarding the role of apoptosis in spontaneous 
regression in neuroblastoma (Yu et al., 2011). We have been unable to detect any significant 
apoptotic cell death by immunohistochemistry for activated caspase 3 (data not shown). 
Whether the processes underlying the apparent regression observed in the SmoA2 cerebellum 
include delayed neuronal differentiation programs, caspase dependent and possible caspase 
independent programmed cell death like autophagic degeneration as implicated in 
neuroblastoma (Kitanaka et al., 2002), are yet to be determined.  
Shh signaling acting through the Smo-Gli axis has been shown to regulate foliation with the 
extent of foliation proportional to the level of signaling (Corrales et al., 2004; Corrales et al., 
2006). However, increased cell-autonomous Shh signaling in the SmoA2 model leads to 
disruptions distinct from phenotypes reported in previous studies (Corrales et al., 2004; 
Hallahan et al., 2004; Corrales et al., 2006; Hatton et al., 2008; Yang et al., 2008). We have 
demonstrated that the disorganized cytoarchitecture of the SmoA2 cerebellum cannot be 
attributed to exclusively increased proliferation of GNPs as defects in foliation and migration 
are not observed in the Ptch conditional knock-out mice (Yang et al., 2008). The effects of 
cell-autonomous Shh signaling on neuronal migration are yet to be understood. Further 
investigation of the SmoA2 gene expression profile will potentially provide further insights 
into the role of Shh signaling on neuronal migration in cerebellar development. 
The stereotyped neuronal circuitry of the cerebellum, critical for its function as a motor 
coordination center, depends on the stereotypic arrangement and distinct morphologies of 
Purkinje cells, granule neurons and the deep cerebellar neurons (Chizhikov and Millen, 
2003). In addition to the reiterative circuitry, it has been shown that topological gene 
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expression patterns in Purkinje cells define longitudinal domains that are essential for proper 
targeting of incoming cerebellar afferents (Wassef et al., 1992; Sotelo and Chedotal, 1997; 
Nishida et al., 2002). Our data reporting the dysplastic phenotype of the SmoA2 cerebellum 
and the lack of any overt neurobehavioral deficiencies question the indispensability of this 
highly stereotypic arrangement for proper functioning of the cerebellum. Both the 
morphology and organization of Purkinje cells and granule neurons are severely disrupted in 
the SmoA2 cerebellum. Yet the lack of detectable behavioral anomalies in the SmoA2 mice 
suggests that the transmissions of afferent and efferent signals seem to be largely maintained. 
Mutant mice such as reeler and staggerer have neuroanatomic defects most pronounced in 
the cerebellum (Goldowitz et al., 1997; Goldowitz and Hamre, 1998; Rice and Curran, 1999) 
with ectopic Purkinje cells, lack of foliation and a reduction in the number of granule 
neurons. These mice display ataxia and uncoordinated movement characteristic of cerebellar 
malfunctions. Yet, intriguingly SmoA2 mutants with some phenotypic similarities in terms of 
disruptions in the laminar architecture with more severe morphological abnormalities in 
multiple cell types, maintain grossly normal motor behavior.  
In summary, through the characterization of the unique phenotype of the SmoA2 model, we 
address key aspects of cerebellar development and function as well as of medulloblastoma 
biology that are yet to be understood. The SmoA2 model is therefore a valuable addition to 
the existing mouse models of medulloblastoma. Medulloblastoma is known to be a cancer 
resulting from deregulated developmental signals. The developmental phenotype of the 
SmoA2 model will therefore allow investigation of cerebellar developmental pathways and 
aberrations thereof that potentially lead to medulloblastoma formation. 
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Materials and Methods  
Generation of the ND2:SmoA1 and ND2:SmoA2 Transgenic Lines 
The ND2:SmoA1 and ND2:SmoA2 transgenic mouse lines were previously described 
(Hallahan et al., 2004; Hatton et al., 2008). All mice were maintained in accordance with the 
NIH Guide for the Care and Use of Experimental Animals with approval from the Fred 
Hutchinson Cancer Research Center Institutional Animal Care and Use Committee 
(IR#1457).  
 
Mouse pathology and Immunohistochemistry 
Mice were anesthetized using CO2 inhalation, the cerebellum removed, and tissue snap-
frozen for RNA studies, GNP isolation or fixed in 10% paraformaldehyde for pathological 
examination. Tissue blocks were paraffin-embedded, cut into 4-µm sections, and stained with 
Hematoxyline and Eosin using standard methods. For immunohistochemical analysis, mouse 
NeuN (Millipore), rabbit Calbindin (Millipore,1:500), rat Ki67 (DAKO), S100 (DAKO), 
antibody was used; secondary antibodies were applied according to Vectastain Elite avidin-
biotin complex method instructions (Vector Laboratories), and detection was carried out with 
3,3'-diaminobenzidine reagent (Vector Laboratories). Sections were visualized with a Nikon 
E800 microscope, and images were captured using the CoolSnap cf color camera (FHCRC 
Scientific Imaging Core). 
 
RNA isolation and Gene expression analysis 
Total RNA was isolated from trizol lysates of each cerebella from P5 WT, Smo/Smo and 
SmoA2 cerebella (n=3 animals per genotype) using the Promega SV-96 RNA isolation 
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kit. Microarray analysis was performed by use of custom designed Affymetrix 
arrays.  Extracted RNA was quantified by use of RiboGreen RNA Quantitation Reagent 
(Invitrogen) and its quality assessed by use of the Agilent RNA 6000 Pico Kit (Agilent, Santa 
Clara, CA) in an Agilent 2100 Bioanalyzer (Agilent). Samples were amplified and labeled by 
use of the Ovation WB protocol (NuGEN Technologies, San Carlos, CA), according to the 
manufacturer’s instructions. The resulting amplified cDNAs were hybridized to Affymetrix 
gene expression chips (Mouse Rosetta Custom Affymetrix 1.0, Affymetrix, Santa Clara, 
CA). Images were analyzed by use of Affymetrix GeneChip Operating Software (GCOS) and 
processed further to derive sequence-based intensities by use of the RMA algorithm. Rosetta 
Resolver system (Rosetta Biosoftware, Seattle, WA) was used to calculate fold changes and 
ratio p-values for the differential expression of genes in each of three replicates of SmoA1 or 
SmoA2 versus a virtual pool of age-matched WT controls (n=3).  p-values were calculated 
using the Rosetta intensity based Affymetric error model. Genes that were present in at least 
two of the three replicates for SmoA1 and SmoA2 with a p-value of <0.01 and absolute 
average fold change of > 2 were considered significantly differentially expressed genes. For 
clustering analysis we first filtered the data to remove data from probe sets whose expression 
levels did not significantly vary across the samples (defined as top 50% least variable). The 
filtered data was then clustered using traditional hierarchical clustering. The GO enrichment 
analysis was carried out using a hypergeometric test for each unique category.  We selected 
significantly enriched categories as any with FDR < 10%.  Microarray data have been 
deposited in the NCBI Gene Expression Omnibus and are accessible through GEO series 
accession number GSE34593. 
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Quantitative Reverse Transcription PCR  
For quantitative reverse transcription PCR (qRT-PCR), RNA was isolated using RNAeasy 
Kit (Invitrogen), DNase (Qiagen) treated and converted to cDNA using the ABI Taqman 
Reverse Transcription kit (Applied Biosystems, Foster City, CA). Reactions were set up 
using Taqman Master Mix and run on an ABI 7000 Sequence Detection System. Taqman 
Gene Expression Assays (Applied Biosystems) were used for mouse Gli1, Gli2, Ptch1, 
Ptch2, Smo. Data were analyzed using ABI GeneAmp SDS software. All of the conditions 
were run in triplicate and normalized to mouse Gapdh control.  
 
Behavioral Tests  
Rotarod Test was conducted using RotaRod (Model 7650; Ugo Basile Comerio, Italy) 
accelerating from 3 to 30 rpm over a 5-min period. The mice were given a trial run prior to 
the timed run where the latency to fall was recorded. 
Footprint assay: The bottom of each foot was coated with non-toxic paint. The mouse was 
allowed to walk through a small tunnel on white paper. Stride length (distance between two 
hind paw prints) and stance width (distance between opposite hind paw prints perpendicular 
to the walking trajectory) were calculated. Each mouse was given a trial run before the final 
run. 
Modified SHIRPA  
SHIRPA stands for SmithKline Beecham Pharmaceuticals; Harwell, MRC Mouse Genome 
Centre and Mammalian Genetics Unit; Imperial College School of Medicine at St Mary’s; 
Royal London Hospital, St Bartholomew’s and the Royal London School of Medicine; 
Phenotype Assessment. Our lab developed an abbreviated behavioral test based on the above 
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that we called the Modified SHIRPA. A single observer evaluated mice for weight, physical 
phenotype – tremor: 1=none/mild 2=marked; body position: 1=elongated 
2=hunched/rounded; tail position: 1=horizontally extended 2=dragging/straub; behavior 
phenotype – grooming: 1=slow/casual 2=none/excessive; spontaneous activity: 1=moderate 
mouse covers all quadrants of cage 2=slow 1-3 quadrants, 3=none/darting/circling; 
locomotor activity: the number of times the mouse places atleast one of its paws on the side 
of the cage over a 2-minute period).  
 
Statistical tests 
 
Student t-test was used to determine if differences observed between measurements obtained 
from two groups being compared were statistically significant. The level of significance was 
set at p < 0.01. 
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Chapter 3 
A novel role of MyoD, a muscle differentiation factor, as a tumor 
suppressor in mouse models of medulloblastoma 
Abstract 
Medulloblastoma, an embryonal tumor of the cerebellum, is the most common pediatric brain 
malignancy. For decades, it has been known that a small subset of medulloblastomas present 
with myogenic differentiation. However, the mechanistic basis and significance of this 
biological anomaly remain to be determined. We have identified previously unknown 
expression of muscle differentiation factor, MyoD in cerebellar tumors from mouse models 
of medulloblastoma as well as in a subset of human medulloblastomas. At a cellular level, 
MyoD is expressed in mitotically active cells and intriguingly, in mouse tumors does not 
activate the muscle differentiation program. To understand the functional consequence of this 
finding in medulloblastoma genesis, we have conducted genetic studies to assess tumor 
formation in the SmoA1 and SmoA2 medulloblastoma models, on a MyoD-deficient 
background. We demonstrate that MyoD acts as a haploinsufficient tumor suppressor as the 
MyoDwt/-; SmoA1 and MyoDwt/-; SmoA2 mice have an accelerated onset of tumors compared 
to MyoDwt/wt; SmoA1 or MyoDwt/wt; SmoA2 mice respectively. Our findings suggest that the 
expression of MyoD might be an oncogene-induced compensatory response in the 
cerebellum to suppress tumor growth by restoring balance between proliferation and 
differentiation, similar to the role of some other bHLH transcription factors. Harnessing this 
latent tumor suppressor network to induce differentiation or cell cycle arrest holds promise 
for future therapeutic interventions.  
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Introduction 
Medulloblastoma is the most common pediatric brain cancer that continues to be the 
leading cause of cancer-related deaths in children below 9 years of age (Oliver et al., 2005). 
Medulloblastomas are classified into various histological categories, which are often 
associated with the underlying molecular basis of tumorigenesis (Gibson et al., 2010; 
Sengupta et al., 2011).  Medullomyoblastoma is a rare histological variant of 
medulloblastoma which presents with myogenic differentiation (Banerjee and Kak, 1973; 
Smith and Davidson, 1984; Rao et al., 1990; Holl et al., 1991; Schiffer et al., 1992; 
Mahapatra et al., 1998). The molecular basis or significance of this pathological anomaly has 
never been investigated.  
MyoD, a basic-helix-loop (bHLH) transcription factor is a critical regulator of the 
muscle differentiation program (Tapscott, 2005). MyoD together with myogenic transcription 
factors Myf5, MRF4 and Myogenin hetero dimerize with members of the E-protein 
subfamily to drive muscle specification, expression of skeletal muscle genes and muscle 
differentiation (Cao et al., 2010).  Studies have demonstrated that forced expression of MyoD 
is able to convert various non-muscle cells such as fibroblasts, chondroblasts, retinal 
pigmented epithelial cells amongst others into the skeletal muscle lineage (Choi et al., 1990; 
Weintraub et al., 1991). Gerber and Tapscott showed that forced expression of MyoD in 
neural tumor lines in vitro largely failed to induce myogenesis (Gerber and Tapscott, 1996).  
There is no experimental evidence of MyoD expression or function in the brain.  
Studies have demonstrated that the expression of MyoD in certain cell types may be 
actively suppressed (Woloshin et al., 1995; Lee et al., 2004). It has been speculated that 
aberrant cell division leading to crisis situations such as neoplastic changes, may result in 
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release of suppression of differentiation factors like MyoD as a way to limit proliferation 
(Tapscott, 2005).  Although historically recognized as a master regulator of the skeletal 
muscle differentiation program, over the years, MyoD has been shown to be associated with 
various kinds of cancers, the functional significance of which is yet to be explored.  
DNA methylation of promoter associated CpG islands is a known mechanism for 
silencing tumor suppressor genes. MYOD was shown to have age related methylation in 
normal colon and hypermethylation in colon cancers (Ahuja et al., 1998). The MyoD CpG 
island shows a progressive increase in methylation during oncogenic transformation of the 
10T1/2 cell line suggesting that the expression of MyoD is unfavorable for oncogenesis 
(Rideout et al., 1994). A recent study shows direct regulation of BRCA1 transcription by 
MyoD suggesting that MyoD may be part of a signaling complex that induces transcription 
of tumor suppressor gene BRCA1, which is reduced in sporadic breast and ovarian cancers 
(Jin et al., 2011). Therefore, the aforementioned findings suggest that the correlation of 
MyoD with cancer is not a mere association but likely an indication of important underlying 
functional consequences. 
The pathophysiology of medullomyoblastoma and the possible function of MyoD in 
tumorigenesis led us to investigate a potential involvement of MyoD in medulloblastoma.  
We demonstrate ectopic expression of MyoD in three mouse models of medulloblastoma in 
proliferative tumor cells. During early cerebellar development, MyoD expression is detected 
in the granule neuron progenitors when they are in the peak of proliferation. The association 
of MyoD with the proliferative phase in normal cerebellar development as well as in tumors 
led us to investigate the functional consequence of MyoD expression. We demonstrate using  
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mouse genetics that MyoD functions as a potential haploinsufficient tumor suppressor in 
mouse medulloblastoma, a novel function for MyoD in the brain. 
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Results 
MyoD is expressed in a subset of human medulloblastomas 
To investigate whether MyoD is expressed in human medulloblastomas, we performed 
quantitative reverse transcription PCR (qRT-PCR) analysis using mRNA from primary tumor 
specimens. Eight out of 29 specimens investigated had MYOD mRNA expression 10-fold 
over normal controls (Table 3.1). Since we normalized the data to normal cerebellar controls 
in which MYOD mRNA expression was undetectable, the analysis results in exaggerated fold 
changes. We therefore show the range of Ct values obtained in MYOD expressing versus 
non-expressing tumors. We have not been able to confirm MYOD protein expression in 
human medulloblastoma clinical specimens using immunohistochemistry due to technical 
challenges associated with immunodetection methods. It remains possible that similar to 
Myf5 in the brain, MYOD is transcribed but not translated in human medulloblastoma cells.   
 
MyoD is expressed in mouse models of medulloblastoma  
Next, to understand the biological significance of MyoD expression, we sought to establish 
an appropriate animal model and investigated MyoD expression in mouse 
medulloblastoma.  qRT-PCR analysis shows elevated MyoD mRNA in tumors from the 
ND2:SmoA2 mice (manuscript in preparation, Chapter 2) relative to WT age-matched adult 
mice (Figure 3.1A). Interestingly, MyoD mRNA is not expressed in SmoA2 cerebella that 
fail to develop into tumors. Next we investigated MyoD protein expression in tumors from 
SmoA2 mice and two additional mouse models of medulloblastoma - ND2:SmoA1 
homozygous (Hallahan et al., 2004; Hatton et al., 2008) and Patched conditional knock out  
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Table 3.1 
Assessment of MyoD mRNA in a subset of human medulloblastomas 
 
Tissue type 
 
No. Of samples 
 
MYOD  
Ct value 
 
PPIA               
Ct average value 
(endogenous control) 
 
Normal cerebellum 
 
 
3 
 
Ct = 40 
 
20.3 
Non-MYOD 
expressing 
medulloblastoma 
 
21 
 
Ct > 35 
 
19.7 
 
MYOD-expressing 
medulloblastoma 
 
 
8 
 
26.1 < Ct < 34 
 
19.7 
 
TABLE LEGEND 
qRT-PCR analysis using primary human medulloblastoma specimens show >10-fold expression of MYOD mRNA in 8 out 
of 29 specimens compared to normal cerebellar controls. CYCLOPHILIN A (PP1A) was used as the endogenous control for 
data normalization, Ct values of which are comparable across the three groups.  
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Figure 3.1  
MyoD is expressed in cerebellar tumors in mouse models of medulloblastoma.  
A. qRT-PCR analysis using mRNA isolated from tumors from SmoA2 mouse model of medulloblastoma and SmoA2 
cerebella (CBL) without tumors show high expression of MyoD mRNA in tumors compared to WT adult CBL as well as 
SmoA2 CBL which have not developed tumors.  β2 microglobulin was used as the endogenous control for data 
normalization. B, C, D, Western blot analyses using protein lysates from WT and SmoA2, SmoA1 and Ptch 
F/F
Math-Cre 
(MC) tumors show strong expression of MyoD in all three tumor types comparable to levels observed in differentiated 
C2C12 muscle progenitor cells used as a positive control in the same experiment (B). MyoD protein is not detectable in 
adult WT CBL or in SmoA2 CBL that do not develop tumors. The analysis was repeated with three different antibodies in 
multiple replicates. Representative blots are shown in this figure. β actin was used as the loading control. 
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mice (PtchF/F Math1-Cre) (Yang et al., 2008). Western blot analyses reveal strong MyoD 
expression at the protein level in tumors from all three medulloblastoma models with no 
detectable expression in WT adult cerebella (Figure 3.1B). MyoD protein expression, similar 
to mRNA, is undetectable in SmoA2 cerebella that have not developed into tumors. This 
demonstrates a correlation between MyoD and tumor status of the mouse cerebellum 
independent of the driving oncogenic mutation. 
 
MyoD is associated with the proliferative status of tumor cells  
The ectopic expression of MyoD, a muscle differentiation factor in cerebellar tumors 
led us identify the cell type and elucidate the proliferative status of the cells it is expressed in. 
Immunofluorescence analyses demonstrate that MyoD is almost exclusively expressed in 
actively proliferating cells that express Ki67 and remains undetectable in the Ki67-negative 
cell population. MyoD and Ki67 expression are also undetectable in the WT adult cerebellum 
(Figure 3.2). 
 
MyoD is expressed during early cerebellar development in wildtype and 
medulloblastoma mouse models 
Medulloblastoma is an example of how aberrations in developmental pathways lead 
to tumorigenesis and many genes deregulated in cancer are known to be involved in normal 
developmental processes (Marino, 2005; Gilbertson and Ellison, 2008). Therefore, we 
investigated if MyoD mRNA and protein are expressed during cerebellar development at 
postnatal day (P) 5 because it is a stage when the cerebellum is undergoing critical 
developmental changes with the granule neuron progenitors (GNPs) in the phase of maximal  
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Figure 3.2 
Cerebellar tumor cells undergoing proliferation express MyoD.  
Immunofluorescence analyses for MyoD and proliferation marker, Ki67 show co-expression of both proteins in proliferating 
tumor cells. MyoD expression is undetectable in non-proliferating Ki67-negative cells in the tumor and the WT adult 
cerebellum which consists of postmitotic mature granule neurons.  DAPI was used as the counterstain. 40X and 100X 
magnification were used for imaging. 
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proliferation. Intriguingly, compared to WT adult cerebellum, we observe elevated MyoD 
mRNA expression in WT P5 cerebellum (Figure 3.3A). The WT adult cerebellum consists of 
post-mitotic differentiated granule neurons where as the WT P5 cerebellum consists of 
actively dividing GNPs. MyoD transcription is further increased in the PtchF/F Math1-Cre 
mice at P5 (Figure 3.3A) as well as in SmoA1 and SmoA2 (data not shown). Consistent with 
mRNA expression, we detect low levels of MyoD protein in WT P5 and SmoA1 P5 
cerebellum, which are phenotypically indistinguishable at this stage (Figure 3.3B).   MyoD 
protein expression is elevated in SmoA2 P5 mice, which similar to the PtchF/F Math1-Cre 
cerebellum, undergoes hyper-proliferation at P5. This finding suggests that MyoD expression 
in early development occurs when GNPs are undergoing proliferation.  
 
Proliferating granule neuron progenitors express MyoD in development 
 We conducted immunohistochemical analysis to identify the cell type in the 
developing cerebellum that expresses MyoD. We observe MyoD expression in a small  
subset of cells in the WT P5 mice primarily in the proliferative outer EGL that are also 
positive for Ki67 (Figure 3.4). The expression pattern is similar in SmoA1 mice, which are 
phenotypically indistinguishable from WT at the P5 stage. MyoD is highly expressed in 
SmoA2 and PtchF/F Math1-Cre cerebella both of which undergo massive GNP 
hyperproliferation leading to an expanded EGL at P5. 
 
MyoD acts as a haploinsufficient tumor suppressor mouse medulloblastoma 
To investigate the biological significance of MyoD expression in cerebellar tumors, we 
investigated the effect of loss of MyoD on tumorigenesis. We crossed ND2:SmoA1 and 
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Figure 3.3 
MyoD is expressed in the proliferative phase of early cerebellar development in mice.  
A. qRT-PCR analysis using postnatal day (P) 5 GNP-enriched cell lysates of cerebella isolated from P5 WT and Ptch F/F 
Math-Cre  mice, show, in comparison to WT adult cerebella, elevated expression of MyoD mRNA in WT P5 cerebella 
which is further increased in P5 Ptch F/F Math-Cre (Ptch KO) cerebella. mRNA from C2C12 differentiated muscle progenitor 
cells was used as the positive control for MyoD expression. β2 microglobulin was used as the endogenous control for data 
normalization. B. Western blot analyses using protein lysates of P5 cerebella show low levels of MyoD protein expression in 
P5 WT and SmoA1 cerebella, which are phenotypically indistinguishable at this stage. The level of expression is increased 
in SmoA2 P5 cerebella and is comparable to endogenous MyoD levels in muscle progenitor C2C12 cells in proliferating 
(PM) and differentiation (DM) states. β actin was used as the loading control. 
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Figure 3.4 
MyoD is expressed in proliferating granule neuron progenitors during cerebellar development.  
Immunofluorescence analyses for MyoD and proliferation marker, Ki67 shows co-expression of both antigens in 
proliferating GNPs in WT, SmoA1, SmoA2 and PtchF/F Math1-Cre (MC) P5 cerebella. In WT and SmoA1 P5 cerebella, 
which are phenotypically identical at this stage, MyoD-positive cells appear to be restricted to the outer external granular 
layer (oEGL). In SmoA2 and PtchF/F Math1-Cre P5 cerebella, the EGL is expanded with hyper-proliferating GNPs, a large 
fraction of which are MyoD-positive. 40X magnification was used for imaging. 
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ND2:SmoA2 mice to MyoD-/wt mice (Rudnicki et al., 1992) to obtain MyoD-/-; SmoA1 and 
MyoD-/-; SmoA2 mice using a 2-step breeding strategy. Kaplan Meier survival analyses 
reveals that the MyoD-/wt ;SmoA1 (n=102)  and MyoD-/wt ;SmoA1(n=83) mice have an 
accelerated onset of tumors compared to  MyoDwt/wt ;SmoA1 (n=108)  and MyoDwt/wt 
;SmoA2 (n=99) mice respectively (p < 0.001) (Figure 3.5). Due to the compromised health 
resulting from the loss of both alleles of MyoD and paucity of MyoD -/-; SmoA2 genotype 
from our genetic cross, we have been unable to recover a sufficient number of MyoD -/-; 
SmoA2 mice required to study the effect of loss of both alleles of MyoD on tumorigenesis. 
Based on histopathological analyses, the MyoD-expressing cells in the mouse tumors do not 
show morphological features of skeletal muscle differentiation (Figure 3.5). 
Through genetic analyses we demonstrate that MyoD acts as a haploinsufficient tumor 
suppressor in cerebellar tumorigenesis in mice.  
 
Regulation of muscle differentiation program genes by MyoD in cerebellar tumors 
To identify the molecules regulated by MyoD consequent to its expression in the 
tumor cells, we investigated by qRT-PCR the mRNA levels of genes known to be regulated 
by MyoD in the muscle differentiation program, namely Myf5, Myog, Desmin, Cdh15 and 
Inhibitors of differentiation (Id) genes Id2 and Id3. Since the biochemical functions of Id 
proteins are similar, and Id1 and Id3 have overlapping expression patterns (Lyden et al., 
1999), we chose to assess Id3 and Id2.  
MyoD expression, as expected, is reduced in the MyoD -/wt; SmoA2 mice compared 
to MyoD wt/wt; SmoA2 (p < 0.05). (Figure 3.6A). Both Myf5 and Myog are up regulated in  
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Figure 3.5  
Loss of MyoD accelerates tumor onset in SmoA1 and SmoA2 models 
Kaplan Meier survival analysis using (A) MyoD wt/wt;SmoA1 (n=108), MyoD wt/-;SmoA1 (n=102) and (B) MyoD 
wt/wt;SmoA2 (n=99), MyoD wt/-;SmoA2 (n=83) show earlier onset of tumors in SmoA1 and SmoA2 mice lacking one 
copy of MyoD. The difference in survival is statistically significant (p < 0.001) (C) MyoD IHC in representative MyoD 
wt/wt;SmoA2 tumor, WT mouse cerebellum (CBL), human rhabdomyosarcoma (RD) and human skeletal muscle show the 
lack of myogenic features in SmoA2 tumors similar to RD also known to overexpress MyoD that fails to cause 
differentiation. 
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Figure 3.6 
MyoD mediated regulation of muscle differentiation program genes in the cerebellar tumors 
A. qRT-PCR analysis using total RNA from MyoD wt/wt; SmoA2 (n=5) and MyoD -/wt; SmoA2 (n=5) tumors show a 
decrease in MyoD transcription in the latter group with the loss of an allele of MyoD. B. qPCR analysis of known targets of 
MyoD. Compared to WT cerebella, mRNA levels of Myogenin, Myf5 are increased in tumors from both groups of mice with 
no significant inter-group difference. Loss of an allele of MyoD causes Id3 levels to increase about 2-fold in MyoD -/wt; 
SmoA2 compared to MyoD wt/wt; SmoA2 tumors (*p<0.01). Cdh15, Desmin and Cxcr4 are not significantly altered. β2 
microglobulin was used as the endogenous control for data normalization for A and B. C qRT-PCR analyses of miR-206 
show reduced expression in both MyoD wt/wt; SmoA2 (n=6) and MyoD -/wt; SmoA2 (n=6) tumors compared to Wt 
cerebella with no significant inter-group difference. Sno 202 was used as the endogenous control for data normalization. D, 
Wt and SmoA2 GNPs were harvested from P5 cerebella and transduced in vitro with GFP (control) and MyoD expressing 
lentiviral constructs. MyoD causes a higher induction of miR-206 in WT GNPs compared to SmoA2 as measured by miR 
assay, Error bars represent standard error of the mean.  
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tumors from both groups but the inter-group difference is not statistically significant (Figure 
3.6B). Consistent with the well-established inverse biological relationship between MyoD 
and Id3, Id3 levels increase by about 2-fold in the MyoD -/wt; SmoA2 mice compared to 
MyoD wt/wt; SmoA2 (p< 0.05) (Figure 3.6B).  
We also investigated expression of miR-206, a microRNA induced by MyoD during 
myogenic differentiation (Rosenberg et al., 2006) and known to have tumor suppressor 
properties in several cancers (Adams et al., 2007; Kondo et al., 2008; Song et al., 2009; 
Taulli et al., 2009; Wang et al., 2011; Chen et al., 2012). Although originally thought to be a 
muscle-specific microRNA, miR-206 has been shown to be enriched in the cerebellum the 
functional implications of which are yet unknown (Olsen et al., 2009). 
Contrary to what we expected, miR-206 levels are reduced in the MyoD expressing 
tumors compared to WT controls, with no discernible difference between MyoD -/wt; 
SmoA2 and MyoD wt/wt; SmoA2 mice (Figure 3.6C). To elucidate this further, we 
overexpressed MyoD in WT and SmoA2 P5 GNPs in vitro using a MyoD-expressing 
lentiviral vector and measured miR-206 levels. Although MyoD induces miR-206 in both 
WT GNPs and SmoA2 GNPs, the expression of miR 206 in WT GNPs is significantly higher 
compared to SmoA2 (Figure 3.6D). This suggests that the oncogenic SmoA2 mutation might 
impair the ability of MyoD to induce miR-206 expression, which together with the 
deficiencies in other muscle differentiation genes may explain the lack of myogenesis in 
these tumors. 
 
MyoD inhibits Id3 transcription        
 To confirm if the transcriptional up-regulation of Id3 associated with down-regulation 
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of MyoD in the MyoD -/wt; SmoA2 tumors (Figure 3.6B) is caused by reduced MyoD, we 
carried out shRNA-mediated silencing of MyoD using two different constructs in GNPs 
isolated from P5 ND2:SmoA2 mice and measured both Id3 and MyoD levels. Pro-
proliferative Id genes are known inhibitors of MyoD-mediated differentiation in myogenesis 
(Jen et al., 1992) and expressed in the cerebellum (Andres-Barquin et al., 2000). qRT-PCR 
analysis reveals that the loss of MyoD causes a transcriptional increase in Id3 levels in 
MyoD-shRNA transduced SmoA2 GNPs compared to untransduced controls in vitro. This 
suggests that MyoD may function to suppress transcription of pro-proliferative Id3 (Figure 
3.7).  
Next, we mined the metaGEO database which consists of expression profiles from 
more than 5,000 distinct gene expression studies across 3 different species (human, mouse, 
rat) to identify to studies in which MyoD expression was significantly variable. We identified 
published study GSE24628 by Gibson et al. as one of the top studies where MyoD expression 
showed the most variability. Interestingly, the study involved gene expression profiling of  
Wnt and Shh driven mouse medulloblastomas, postnatal GNPs and embryonic dorsal 
brainstem cells (Gibson et al., 2010). Consistent with our findings, we find increased 
expression of MyoD in the Shh-driven medulloblastomas followed by P7 GNPs compared to 
the other conditions (Figure 3.8). In addition, in this dataset we find an inverse correlation 
between MyoD and Id3 consistent with our findings - the Shh-driven medulloblastomas have 
high MyoD expression and low Id3 levels whereas the Wnt-driven medulloblastomas have 
low MyoD and high Id3. These findings combined suggest that MyoD has an inhibitory 
effect on Id3 transcription in medulloblastoma. 
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Figure 3.7 
Loss of MyoD leads to increased Id3 transcription 
SmoA2 P5 GNPs were harvested and transduced in vitro with two different MyoD-shRNA expressing lentiviral vectors. 
Compared to untransduced controls, shRNA-mediated silencing of MyoD results in increased Id3 transcription as revealed 
by qPCR analysis. β2 microglobulin was used as the endogenous control for data normalization. 
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Figure 3.8  
Inverse Correlation between MyoD and Id3  
Exploration of the metaGEO database to find studies in which MyoD expression is significantly variable, led to the 
identification of study GSE24628 involving gene expression profiling of Wnt-driven mouse medullblastomas (Wnt MB), 
Shh-driven mouse medulloblastomas (Ptch-MB), postnatal day (P)7 GNPs and embryonic day (E) 16.5 dorsal brain stem 
cells.  Box-plots show MyoD and Id3 gene expression to be inversely correlated in this study.  
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MyoD induces muscle differentiation in primary human medulloblastoma cells 
The tumor suppressor role of MyoD in mouse models of medulloblastoma led us to 
investigate the functional significance of MyoD expression in human medulloblastoma.  For 
in vitro studies, we chose to generate a patient-derived primary medulloblastoma line instead 
of using established cell lines since the former represents the molecular profile of the original 
tumor more appropriately. We expressed MyoD using a lentiviral vector in a patient-derived 
primary medulloblastoma cell line that lacks endogenous MYOD expression as verified by 
qRT-PCR analysis. Consequent to MyoD expression, the cells assumed a 
filamentous/fibrillar morphology suggesting possible neuronal or myogenic differentiation. 
Immunocytochemical staining for neuronal differentiation marker beta tubulin (Tuj1) and 
muscle differentiation marker Myosin heavy chain (MHC) confirmed that the tumor cells had 
differentiated into MHC positive myofibrils (Figure 3.9).  
Our finding showing myogenesis in human medulloblastoma primary cells following 
forced expression of MyoD in vitro is different from our observation in mouse 
medulloblastoma where MyoD does not induce myogenesis in vivo but acts as a tumor 
suppressor. Therefore, while these differences could stem from differences in MyoD dosage 
in vivo versus in vitro, it is also possible that the function of MyoD as a tumor suppressor in 
mice is through a pathway independent of myogenesis. Whether the terminal differentiation 
observed in human cells contributes to tumor suppression in human tumors is yet to be 
determined.  
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Figure 3.9 
Expression of MyoD induces myogenic differentiation in human medulloblastoma primary cell line 
MyoD was expressed in a patient-derived medulloblastoma primary cell line using a lentiviral vector. Immunofluorescence 
analyses were carried out using antibodies for neuronal differentiation marker, beta tubulin (Tuj1) and muscle differentiation 
marker, Myosin heavy chain (MHC).  Following MyoD expression, the tumor cells assumed fibrillar morphology that stain 
positive for MHC. 
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Discussion 
In this study, we have discovered a novel tumor suppressor function of muscle 
differentiation factor, MyoD in mouse medulloblastoma. We show that MyoD is ectopically 
expressed both at the transcript and protein level in cerebellar tumors from three different 
mouse models of medulloblastoma namely ND2:SmoA1, ND2:SmoA2 and Patched 
conditional knock-out mice (Hallahan et al., 2004; Hatton et al., 2008; Yang et al., 2008). 
These models have been genetically engineered such that they have constitutive Shh 
signaling in the cerebellum, which leads to tumorigenesis. Through mouse genetic studies, 
we show that the SmoA1 and SmoA2 mice on a MyoD deficient background have an 
accelerated onset of tumors. The consequence of loss of only a single allele of MyoD is 
profound and intriguing. This finding is supported by similar dosage effects observed for 
other bHLH family transcription factors (Erickson and Cline, 1991; Bain et al., 1994; Zhuang 
et al., 1994; Lyden et al., 1999).  
Molecular characterization of human medulloblastomas categorizes the disease into 
four subtypes  – SHH-driven, WNT-driven, MYC amplified and a subtype with yet unknown 
genetic determinants (Taylor et al., 2011). The vast majority of the existing mouse models 
represent Shh-driven medulloblastoma (Hatten and Roussel, 2011). Due to the lack of mouse 
models that recapitulate other subtypes of medulloblastoma except for a recent Wnt-driven 
model (Gibson et al., 2010), our findings are specific to the Shh-driven mouse 
medulloblastomas. It is possible that these results are specific for the Shh-driven mouse 
models since MyoD is known to be influenced by Shh signaling (Tapscott, 2005; Barakat et 
al., 2010). 
! 79!
MyoD has not been previously known to be expressed or have a functional role in the 
brain. A study by Kablar et al. suggested that the promoter of MyoD1 is permissive to 
expression in the brain but different regulatory elements within the promoter (eg. negative cis 
regulatory element) prevents MyoD1 from being expressed in the brain (Kablar, 2002). 
Therefore, it is possible that the effect of the negative regulatory elements is overcome as a 
consequence of the oncogenic mutation leading to the expression of MyoD, a transcription 
factor that has the capacity to drive differentiation. The study showing expression of Myf5 as 
an axonal marker in the brain at the transcript level (Tajbakhsh and Buckingham, 1995; 
Daubas et al., 2000) sets a precedent for the discovery of other myogenic regulators in the 
brain with functions potentially different from those known in the skeletal muscle lineage.  
We demonstrate MYOD expression at a transcriptional level in a small subset of 
human medulloblastomas.  Although molecular characterization of these medulloblastomas 
was beyond the scope of our study, we assessed GLI1 levels to identify the SHH-driven 
subtype and did not find a correlation between MYOD and GLI1 expression (data not shown). 
This suggests that MYOD expression in human medulloblastoma may not be subtype-
specific. Our inability to detect MYOD protein in human medulloblastoma cells could be due 
to technical difficulties associated with immunodetection or a true absence of MYOD 
translation in human tumors. We show that forced expression of MyoD in a human 
medulloblastoma primary line lacking endogenous MYOD mRNA, causes the tumor cells to 
differentiate and express myosin heavy chain protein, a structural protein of the skeletal 
muscle lineage. It has been shown that forced expression of MyoD largely fails to induce 
myogenesis in neural tumor cell lines except for a medulloblastoma and a glioblastoma line, 
due to the deficiency of factor/s needed for myogenesis (Gerber and Tapscott, 1996). It is 
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possible that the potential myogenesis following forced expression of MyoD in the one 
primary medulloblastoma line we tested, is yet another rare exception. Alternatively, the 
myogenic factors downstream of MyoD are lost in cell lines but preserved in primary lines 
that more closely represent the original tumors. The rare occurrence of human 
medullomyoblastoma makes it challenging to determine if expression of MYOD is the 
underlying molecular basis of this particular histological variant. Aberrations in cell cycle 
control and terminal differentiation are fey features of cancer cells (Gerber and Tapscott, 
1996). Whether the induction of terminal differentiation by MyoD in human 
medulloblastoma cells is a way of limiting tumor growth is a question yet to be answered. 
We are unable to detect myogenic differentiation in mouse medulloblastomas that express 
high MyoD. Therefore, based on our findings, it remains possible that the role of MyoD in 
driving myogenesis may be independent of its role as a tumor suppressor in mice.  
MyoD has not been shown to have a role in oncogenesis but several studies associate 
MyoD with different kinds of cancers, which indicates a possible functional significance. 
DNA methylation of promoter-associated CpG islands of MyoD has been found in colon and 
prostate cancer (Ahuja et al., 1998; Mishra et al., 2010) and chemically-induced oncogenic 
transformation of 10T1/2 cells in vitro shows a progressive increase in MyoD promoter 
methylation (Jones et al., 1990; Rideout et al., 1994), a mechanism well known to silence 
tumor suppressor genes in cancer (Hatada et al., 2006). A recent study shows a direct 
correlation between MYOD and BRCA1 expression in sporadic human breast cancer a large 
percentage of which have reduced normal BRCA1 as well as MYOD (Jin et al., 2011). 
MyoD directly induces BRCA1 transcription with c-myb and is thought to play a role in 
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breast cancer susceptibility (Jin et al., 2011). These studies point at a potential tumor 
suppressor role of MyoD in cancer. 
Malignant transformation involves complex genetic changes that commonly lead to 
activation of oncogenes and loss of tumor suppressor genes that provide a proliferative 
growth advantage. However, mammalian systems also have inherent defense mechanisms 
against oncogenic stimuli that cause cells to undergo apoptosis, senescence (Lleonart et al., 
2009; Romagosa et al., 2011) or differentiation (Watt et al., 2008) as fail-safe mechanisms to 
prevent uncontrolled proliferation and consequent tumorigenesis. Networks that drive 
proliferation often harbor intrinsic growth-suppressive properties that are reflected in the 
phenomena of oncogene-induced apoptosis (eg. p53 induction by oncogenes Myc, E2F) or 
oncogene-induced senescence (Ras-induced activation of chromatin modifying factors that 
produce a repressive state in vitro)(Lowe et al., 2004).  
Although counterintuitive, a number of tumor suppressor genes are overexpressed in 
cancer to possibly inhibit uncontrolled proliferation. Examples include p16INK4a (Romagosa 
et al., 2011); TP73 of the p53 family associated with improved survival outcomes in 
medulloblastoma patients (Castellino et al., 2007); pRb2/p130 in hepatocellular carcinoma 
(Huynh, 2004), Cdx2 in colorectal adenocarcinoma (Witek et al., 2005); S100A11 in 
pancreatic carcinogenesis (Ohuchida et al., 2006) and that of wildtype p53 in a subset of 
gliomas which also express antiapoptotic protein Bcl-2 to potentially subvert p53 mediated 
apoptosis (Alderson et al., 1995). In light of the above examples, the expression of MyoD in 
tumors possibly represents a novel latent fail-safe mechanism in the cerebellum induced in 
response to an oncogenic signal. Interestingly, in this case, MyoD is not normally expressed 
in the normal adult cerebellum but is activated in response to the oncogenic stimuli. Its 
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activation in an ectopic environment may explain why even though MyoD is able to prolong 
survival as demonstrated by our genetic studies, it acts as only a partial brake on 
tumorigenesis due to the timing of when it is activated and/or suboptimal activation of 
downstream targets. 
Our study shows that MyoD expression correlates with the proliferative status of cells 
be it during normal GNP proliferation in development or in tumors. MyoD is undetectable in 
WT or SmoA2 cerebella that do not develop into tumors even though they are genetically 
identical to those that that do. This suggests MyoD is expressed in response to uncontrolled 
proliferation in tumors or a high degree of normal proliferation during postnatal GNP 
expansion development.  Our finding showing MyoD expression exclusively in Ki67-
positive proliferating cells supports this hypothesis. The prolonged proliferative phase in 
normal cerebellar development makes the cerebellum vulnerable to neoplastic changes 
(Wang and Zoghbi, 2001). Thus it remains possible that MyoD expression in WT GNPs 
during normal development is a preemptive protective mechanism to prevent potential 
transformational events common in highly proliferative tissues  
Mouse medulloblastomas that express MyoD, also express Myf5 and Myogenin 
amongst the MyoD-regulated genes that were assessed in this study. However, the lack of 
expression of other targets as well as the absence of features of skeletal muscle 
differentiation in the tumors suggest that the tumor suppressor function of MyoD is not 
exerted through its known targets in the muscle differentiation program. Additionally, Myf5 
and Myogenin levels are not significantly different between the early onset MyoD -/wt; 
SmoA2 and late onset MyoD wt/wt; SmoA2 tumor groups, which further suggests the 
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presence of alternative downstream players in the MyoD-regulated tumor suppressor 
pathway.  
Id proteins antagonize MyoD-mediated differentiation by sequestering E proteins, the 
heterodimeric partner of MyoD during skeletal muscle development (Jen et al., 1992). The 
pro-proliferative Id proteins function in tumorigenesis (Zebedee and Hara, 2001; Ruzinova 
and Benezra, 2003; Sikder et al., 2003), are expressed in the nervous system (Andres-
Barquin et al., 2000) and inhibit neural differentiation (Lyden et al., 1999). We observe a 
difference in Id3 transcript levels between tumors from MyoD wt/wt; SmoA2 versus     
MyoD -/wt; SmoA2, with the loss of MyoD in the latter associated with an increase in Id3.  
A partial reduction in Id dosage has been shown to inhibit tumor growth and decrease tumor 
angiogenesis (Lyden et al., 1999). An inverse correlation between MyoD and Id3 is also 
observed in the gene expression study by Gibson et al (Gibson et al., 2010) comparing 
different medulloblastoma subtypes and GNPs. Therefore it is possible that MyoD-mediated 
Id3 suppression in the MyoD wt/wt; SmoA2 mice contributes to the improved survival in this 
group and the loss of this suppression results in accelerated tumor onset in MyoD -/wt; 
SmoA2 mice. The regulation of Id3 by MyoD in the tumors is further supported by our in 
vitro data showing an increase in Id3 transcription following shRNA-mediated MyoD 
silencing in P5 GNPs that have high levels of endogenous MyoD.  
miR-206 although originally recognized as a muscle-specific microRNA (Kim et al., 
2006) and a target of MyoD in the muscle differentiation program (Rosenberg et al., 2006),  
has been recently shown to be enriched in the cerebellum (Olsen et al., 2009). miR-206 has 
tumor suppressor functions in various cancers namely metastatic lung cancer, endometrial 
cancer and breast cancer (Adams et al., 2007; Kondo et al., 2008; Song et al., 2009; Taulli et 
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al., 2009; Wang et al., 2011; Chen et al., 2012). Although yet to be studied in the context of 
medulloblastoma, microRNA profiling shows miR-206 to be one of 24 miRNAs down-
regulated in proliferating mouse GNPs and medulloblastomas when compared to mature 
mouse cerebellum (Uziel et al., 2009). Here we validate that miR-206 is down-regulated in 
medulloblastoma. However, since miR-206 is induced by MyoD during muscle 
differentiation, the down regulation of miR-206 in MyoD-0expressing tumors is 
counterintuitive. This conundrum is explained by our in vitro data, which shows that forced 
expression of MyoD induces miR-206 but compared to WT GNPs, miR-206 induction is 
reduced in the SmoA2 GNPs. This indicates a disrupted MyoD-mediated miR-206 regulation 
in the oncogenic context both in vitro and in vivo. The dysregulation of the downstream 
effector miR-206 may partly explain why MyoD is unable to induce myogenesis or acts as a 
partial brake on tumorigenesis in mouse medulloblastoma. 
Tumor cells possess the potential for self destruction – the very oncogenic mutations 
required for uncontrolled proliferation can unbridle tumor suppressor programs still intact in 
the cells but not active since the molecular networks connecting proliferation and tumor 
suppression become uncoupled in cancer(Lowe et al., 2004). Therapeutic interventions 
directed at harnessing one’s own latent tumor suppressor networks that are originally coupled 
to proliferative pathways but uncoupled in cancer, hold promise for treatment of cancer 
(Lowe et al., 2004). Chen et al showed that a synthetic peptide fragment of MyoD with high 
affinity for Id1 reduced proliferation and induced apoptosis in breast and colon cancer cells 
in vitro (Chen et al., 2010). Although the association of MYOD and medullomyoblastoma is 
yet unknown, its tumor suppressor function in mice and possible expression in a subset of 
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human medulloblastomas makes the MyoD-mediated latent tumor suppressor network of 
therapeutic interest.  
In summary, our study unveils an ectopic expression pattern of MyoD in 
medulloblastoma and cerebellar development in mice and demonstrates a novel tumor 
suppressor function of MyoD, hitherto recognized as exclusively a muscle differentiation 
factor. This study demonstrates how a protective biological network can be activated to 
counter oncogenic effects thereby paving the path for developing therapies that would allow 
activation of such an inherent fail-safe mechanism to block tumorigenesis. 
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Materials and Methods 
ND2:Smo Transgenic and MyoD wt/- Mouse Lines 
The ND2:SmoA1, ND2:SmoA2 transgenic mouse lines, Patched conditional knock out mice 
and MyoD +/- mice and genotyping protocols have been previously described (Rudnicki et 
al., 1992; Hallahan et al., 2004; Hatton et al., 2008; Yang et al., 2008). All mice were 
maintained in accordance with the NIH Guide for the Care and Use of Experimental Animals 
with approval from the Fred Hutchinson Cancer Research Center Institutional Animal Care 
and Use Committee (IR#1457).  
 
Mouse pathology and Immunohistochemistry 
Mice were anesthetized using CO2 inhalation, the cerebellum removed, and tissue snap-
frozen for RNA studies, GNP isolation or fixed in 4% paraformaldehyde for histological 
examination. Fixed tissue were paraffin-embedded, cut into 4-µm sections. For 
immunofluorescence analyses, MyoD (mouse 5.8A, BD Biosciences 1:200), rabbit Ki67 
(Novocastra, 1:100) followed by anti-mouse Fab-fragment ME-kit, secondary CSA-SA 
Alexa 350 polymer (Molecular probes, Invitrogen) and Alexa 647 for Ki-67. For 
Immunohistochemical analyses, antibodies used were MyoD1 (mouse 5.8A, BD Biosciences 
1:1000), followed by anti-mouse Fab frag-ME kit/CSA detection kit. Data was confirmed 
using additional MyoD antibodies (rat Active motif 1:50) and (rabbit Santa cruz M-318). 
Sections were visualized with Nikon 800 or  DeltaVision Deconvolution microscope 
(FHCRC Scientific Imaging Core). 
 
Quantitative Reverse Transcription PCR  
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For quantitative reverse transcription PCR (qRT-PCR), RNA was isolated using miRNAeasy 
Kit (Invitrogen), DNase (Qiagen) treated and converted to cDNA using the ABI High 
Capacity Reverse Transcription kit (Applied Biosystems, Foster City, CA). Reactions were 
set up using ABI SYBR green or Taqman Master Mix and run on an ABI 7000 Sequence 
Detection System. Taqman Gene Expression Assays (Applied Biosystems) were used for Ms 
MyoD, Hs MYOD, Hs PPIA, Ms b2m, Hs GLI1, and ABI Taqman miR assays for mir206 and 
sno202. Primer sequences designed using Primer3 software (Rozen and Skaletsky, 2000) for 
the SYBR assay are as follows: Cpha endogenous control Forward 5’-
gagctgtttgcagacaaagttc-3’, Reverse 5’-ccctggcacatgaatcctgg-3’ (kind gift from the lab of Dr. 
Sunil Hingorani ); MyoD1 Forward 5’- cccgcgctccaactgctctg-3’, Reverse 5’-
ggctcgacacagccgcactc-3’; Desmin Forward 5’-ataccgacaccagatccagtccta-3’, Reverse 5’-
tgcctcatcagggagtcgtt-3’ ; Myogenin  Forward 5’-gtcccaacccaggagatcatt-3’, Reverse 5’-
gacgtaagggagtgcagattgtg-3’; Cadherin15  Forward 5’- catgctgtcactcagtccaggag-3’, Reverse 
5’- gggcgatctgagtgacagca-3’; Myf5 Forward 5’- gcatgcctgaatgtaacagc-3’,Reverse 5’- 
gctcggatggctctgtagac-3’; Id2 Forward 5’- ccagagacctggacagaacc-3’; Reverse 5’- 
attcagatgcctgcaaggac-3’; Id3 Forward 5’- gaggagcttttgccactgac-3’; Reverse 5’- 
gagagagggtcccagagtcc-3’, (kind gift from the lab of Dr. Stephen Tapscott), CXCR4 Forward 
5’-acggctgtagagcgagtgtt-3, Reverse 5’- ggtgggcaggaagatcctat-3’. Data were analyzed using 
ABI GeneAmp SDS software. All conditions were run in triplicate and normalized to mouse 
b2m or Cpha and human PPIA endogenous control.  
 
Western Blot Analysis  
Protein lysates were prepared using (0.5% TritonX, 0.25% sodium deoxycholate, 1mM 
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PMSF, 10mM NaF, 1mM Na-orthovanadate, Roche protease inhibitor cocktail) lysis buffer. 
Equal amounts of proteins from each sample (25 µg) were subject to SDS-PAGE using 
NuPAGE Novex Bis-Tris gels (Invitrogen), X-Cell SureLock Mini cell (Invitrogen), 
transferred to nitrocellulose membranes, and probed with three different antibodies MyoD 
(C-20, Santa Cruz Biotechnology, 1:200), (BD Biosciences, 1:150) and rabbit 6975b (kind 
gift Dr. Stephen Tapscott), loading control β-actin (Abcam, 1:5000). Horseradish peroxidase 
conjugated secondary antibodies were obtained from Jackson Immunoresearch and used at 
1:8000 dilutions. Proteins were detected by incubating membranes in chemiluminiscent 
substrate (ECL kit, Pierce) followed by exposure to X-OMAT Kodak Scientific Imaging 
Film.  
 
Lentiviral constructs 
MyoD-expressing lentiviral vector was designed by cloning mouse MyoD into 
pRRLSIN.cPPT.PGK-GFP.WPRE lentiviral vector backbone (Addgene plasmid 12252) 
using BamH1 and Sal1 sites replacing GFP cassette (gift from Tapscott lab). The original 
vector was used as the GFP expressing control. Mouse GIPZ lentiviral MyoD shRNAmir set 
(Open Biosystems, Thermo Fisher Scientific) was used for MyoD knockdown. Recombinant 
replication incompetent lentivirus was produced as previously described (Munoz et al., 2011) 
 
Preparation of granule neuron precursor (GNP) cultures, primary medulloblastoma 
culture, lentiviral transduction and immunocytochemistry  
GNPs were harvested from P5-P7 mice and primary cultures were established as previously 
described (Lee et al., 2009).  Primary medulloblastoma lines were established as described 
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previously(Pollard et al., 2009). Lentiviral transductions were carried out with multiplicity of 
infection 2 for GNPs and 10 for primary medulloblastoma line and all assays were carried 
out 72 hours post transduction. Antibodies used for immunocytochemistry were Myosin 
Heavy Chain (mouse MF 20, DSHB) and Tuj1  (mouse, Sigma), secondary Texas Red  
 
Survival Analysis  
Survival curves were plotted using Kaplan-Meier method and compared using two-sided log-
rank test. All statistical analyses were performed in R statistical systems (http://www.r-
project.org). These estimates were made using two-sided log-rank test at p < 0.001 
significance level. Survival analyses used animal death times as events and mice that were 
still alive at the time of analysis as censored data. 
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Chapter 4 
Role of extrinsic Sonic Hedgehog signaling in the tumor microenvironment 
for the growth and maintenance of non-Sonic hedgehog driven 
medulloblastomas 
Introduction 
It is well accepted that mutations causing aberrations in the intrinsic Shh signaling 
pathway, lead to proliferation of tumorigenic cells in numerous types of cancers(Ruiz i 
Altaba, 2008) including medulloblastoma (Gilbertson and Ellison, 2008). A study by Yauch 
et al. sheds light on the extrinsic role of Shh by which it can activate the pathway in non-
malignant stromal cells that are part of the tumor microenvironment and can support tumor 
growth through mechanisms not yet known (Ruiz i Altaba, 2008; Yauch et al., 2008). This 
study reinforces the critical role of the stromal microenvironment on epithelial tumor growth.  
It is known that 25-30% of medulloblastoma cases are caused by activating gene 
mutations in the SHH pathway, as shown by molecular profiling studies which categorize 
medulloblastomas into five subtypes based on their molecular signatures (Thompson et al., 
2006). Given the role of Shh in extrinsic signaling in the tumor micro-enviroment in other 
types of cancer (Yauch et al., 2008), Shh could play an additional role even in the other four 
Non-Shh medulloblastoma subtypes, by creating a tumor microenvironment favorable for 
tumor proliferation and maintenance. This is important because in addition to therapies 
targeted against medulloblastoma tumor cells, targeting tumor microenvironment may be 
necessary for successful treatment. Furthermore, survival of medulloblastoma cells has been 
shown to be dependent on their microenvironment in primary culture experiments(Rutka et 
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al., 1987). Therefore, if medulloblastomas lacking activating Shh mutations respond to Shh 
inhibition in pre-clinical mouse studies, it will be reasonable to include Shh antagonists as 
part of a multi-agent therapy for all recurrent medulloblastoma patients.  This would 
potentially benefit many more children affected by this cancer. On the other hand, if 
medulloblastomas that lack activating Shh mutations do not respond to Shh inhibition in pre-
clinical studies, it will be important to focus human clinical trials on patients only with Shh 
pathway mutations.  
Cyclopamine, a Smo-antagonist (Taipale et al., 2000) effectively kills mouse and 
human medulloblastoma cells(Berman et al., 2002) and a pre-clinical study conducted in our 
lab has shown that IPI-926, a derivative of cyclopamine targeting Smo, causes dramatic 
regression of medulloblastomas in Patched conditional knock-out mice (Yang et al., 2008) 
that develop Shh-driven aggressive medulloblastomas by postnatal day 21. Understanding 
the role of extrinsic Shh signaling in the microenvironment and effect on non-Shh driven 
medulloblastomas will be crucial for making therapy decisions and patient care. In this study 
we determined if IPI-926 induces remission in mouse models with xenografts from human 
medulloblastomas that are not caused by mutations in the SHH pathway. 
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Results  
Determination of IPI-926 Dosage Regimen  
We generated a mouse allograft tumor line by orthotopically transplanting tumor cells from 
the genetically engineered mouse model (GEMM) of medulloblastoma - Ptch1 conditional 
knock out model (Ptch1 flox/flox; Math1-Cre) (Yang et al., 2008). Our previous studies 
demonstrated complete tumor regression in the GEMM Ptch1 flox/flox; Math1-Cre mice 
following IPI-926 treatment (data not shown). The allograft line carrying the same tumors 
was therefore used to determine the best tolerated dose for athymic mice as well as served as 
a positive control in the preclinical trial. The doses tested were 20mg/kg administered daily, 
40mg/kg administered daily, 40mg/kg administered thrice weekly (in this case there was an 
interval of 72 hours between the last dose of the week given on Friday and first dose the 
following week given on Monday) or 40mg/kg administered every 48 hours. Using 
quantitative RT-PCR, we measured mRNA levels of the Shh pathway effector Gli1 as an 
endpoint (Figure 4.1) with respect to untreated controls. Based on the data, we determined 
that 40mg/kg of IPI-926, every 48 hours to be the best tolerated dose that led to the most 
effective inhibition of the Shh pathway (Figure 4.1). We also observed dramatic regression of 
tumors in these mice.  
 
Effect of IPI-926 on human xenograft medulloblastomas 
Tumors from Ptch flox/flox; Math1-Cre mice, human xenograft lines L2123 and L984, 
both Non-SHH driven, were transplanted orthotopically into cerebella of athymic recipient 
mice. Based on natural history study of tumor onset in each of these lines, we enrolled mice 
in the drug trial prior to manifestation of clinical symptoms of tumor. IPI-926  
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Figure 4.1 
Determination of best-tolerated dose of IPI-926 by assessment of Shh target Gli1 in Shh-driven mouse 
medulloblastomas 
Athymic mice with Ptchflox/flox-Math1-Cre allograft tumors were administered by daily gavage IPI-926 20mg/kg daily (n=2), 
40mg/kg daily (n=1), 40mg/kg every 48 hours (n=2) or 40mg/kg thrice weekly (n=1) (in which case was an interval of 72 
hours between the last dose of the week given on Friday and first dose the following week given on Monday). mRNA was 
harvested from the tumors to measure Gli1 levels by qPCR relative to untreated controls (UnTx Cntrl). β2-microglobulin 
was used for data normalization. 40mg/kg every 48 hours was determined to be the best tolerated dose that caused effective 
inhibition of Gli1 levels.  
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and vehicle were administered by oral gavage for 6 weeks, 40mg/kg every 48 hours. Kaplan-
Meier survival curves in Figure 4.2 and 4.3 summarize our results.  
After 6 weeks of IPI-926 treatment, athymic mice with Ptch flox/flox; Math1-Cre 
allograft tumors survived where as all mice in the vehicle arm succumbed to tumors (Figure 
4.2). Even though the mice were asymptomatic at enrollment, as we had expected based on 
our natural history study, the mice had histological tumors at enrollment.  
Hematoxylin-Eosin staining shows histology of the cerebella of mice A, B, C (marked  
 
with boxes in Kaplan Meier curve) at pre-enrollment, in the IPI-926 drug arm at 6 weeks and 
after 6 weeks of treatment when the tumors grew back.  
With the same dosing regimen, we did not observe an effect of IPI-926 treatment on 
tumors from either the L2123 (Figure 3) or L984 (Figure 4) human medulloblastoma lines. 
These mice were also asymptomatic at enrollment.   
 
Conclusions 
Our preclinical studies demonstrate that IPI-926 did not lead to improvement in survival for 
mice that carried Non-SHH driven human medulloblastomas.  The positive control consisting 
of mice carrying allograft tumors from Patched conditional knock out mice (Shh-driven) 
worked well and a clear survival advantage was observed. This finding is important in 
making recommendations that human clinical trials using IPI-926 should include only 
patients with SHH-driven medulloblastomas. For others, advantages of SHH inhibition may 
be further tested by including SHH antagonists as part of a multi-agent therapy and/or in 
metronomic trials.  
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Figure 4.2 
Response of Ptchflox/flox-Math1-Cre allograft tumors to IPI-926 treatment 
Ptchflox/flox-Math1-Cre allograft tumors were harvested from GEMM tumors and transplanted orthotopically into cerebella of 
athymic (Nu/Nu) recipients. Mice were randomized into the IPI-926 (n=5) or vehicle (n=5) arms and enrolled into the 
preclinical trial 22 days post transplant when most mice were symptomatic. 40mg/kg IPI-926 was administered by oral 
gavage every 48 hours for 6 weeks. Kaplan Meier survival curves show that at 6 weeks all mice in the drug arm survived 
while those in the vehicle arm succumbed to tumors. However, after withdrawal of IPI-926, the tumors grew back and mice 
eventually succumbed to tumors. A represents a mouse in the vehicle arm that succumbed to tumor, B represents a mouse in 
the IPI-926 arm whose tumor regressed in response to the drug and C represents a mouse in the IPI-926 arm that succumbed 
to tumor after treatment was stopped. Hematoxylin Eosin staining of representative brain sections from A, B and C are 
shown with tumors consisting of hematoxylin stained mass of blue cells. 
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Figure 4.3 
Response of human medulloblastoma xenograft tumors to IPI-926 treatment 
Tumors from human medulloblastomas xenograft lines L984 (indeterminate mutation) and Non-SHH driven L2123 were 
transplanted orthotopically into cerebella of athymic (Nu/Nu) recipients. Mice were randomized into the IPI-926 or vehicle 
arms and enrolled in the preclinical trial 20-33 days post transplant. All mice were asymptomatic at this stage. 40mg/kg IPI-
926 was administered by oral gavage every 48 hours till all mice in either arm succumbed to tumors. Kaplan Meier survival 
curves show that IPI-926 has no effect in the human tumor lines tested since all mice in both drug and vehicle arm succumb 
to tumors.  
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Chapter 5 
Conclusions and Future Directions 
SmoA2 studies 
Through my studies as described in Chapter 2, I have demonstrated the fundamental 
differences between two activating point mutations, SmoA1 and SmoA2, in the same domain 
of a single gene. Both mutations lead to constitutively active Shh signaling that result in 
medulloblastoma genesis but have completely disparate effects of cerebellar development. 
While the SmoA1 mutation does not lead to any apparent developmental defects, the SmoA2 
mutation leads to massive disruptions starting early in development. SmoA1 and SmoA2 lead 
to different global transcriptional profiles in the early postnatal cerebellum.  One of the 
important next steps is to understand the cell-autonomous effects of the SmoA2 mutation 
with cues from the gene ontology categories represented by the gene expression data. First, in 
light of the extensive neuronal migration defects observed in the cerebellum, it will be 
interesting to investigate how the SmoA2 mutation affects GNP migration patterns in 
controlled in vitro experiments using advanced time lapse imaging techniques. Second, the 
SmoA1 and SmoA2 mutations potentially harness different downstream effectors, 
identification of which would further our understanding of the mechanics of the Shh 
pathway.  Immunoprecipitation assay followed by mass spectrometry based proteomic 
identification of molecules that directly interact with SmoA1 and SmoA2 would help in 
characterization of novel molecules in the Shh pathway involved in signal transduction from 
the membrane to the nucleus. Third, in both SmoA1 and SmoA2 models, we observe tumors 
initiating from the pial surface. Characterization of this niche will be an important step in 
furthering our knowledge about medulloblastoma biology. One possibility is that 
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chemoattractants or trophic factors secreted from the leptomeningeal membranes (pia and 
arachnoid mater) contribute to making a niche conducive for neoplastic cells to survive and 
proliferate. Surgical implantation of beads soaked with the known secreted factors like Sdf1-
α, TGF β amongst others, into brains of WT and mutant brains may allow us to study the 
effect of these factors on attracting or favoring the persistence of neoplastic cells in this 
niche. It is also possible that additional cell intrinsic effects in the SmoA1 or SmoA2 
expressing cells cause a sub-population of cells to reside along the nutrient rich pial surface 
whereas others that migrate inwards regress or differentiate into normal granule neurons. By 
design of the transgenes, every GNP is expected to express the SmoA1 or SmoA2 oncogene, 
yet majority of the GNPs seem to mature into normal neurons while atypical cells remain 
along the pial surface. Using laser capture technology, isolation of the atypical cells along the 
pial surface and the normal mature neurons to compare gene expression profiles will allow us 
to uncover additional cell intrinsic “second hits” that allow a subpopulation to initate tumors. 
Fourth, perhaps the most intriguing aspect of the SmoA2 phenotype is the normal 
neurobehavior of the mice despite the completely disrupted cerebellar cytoarchitecture. 
Injection of transynaptic viral tracers into the SmoA2 brains (Boldogkoi et al., 2009) 
followed by two-photon/confocal microscopy will allow mapping of the cortico-cerebellar 
circuitry to help understand how cerebellar functionality is maintained.  
 
MyoD Studies 
Through my studies described in chapter 3, I have discovered a hitherto unknown expression 
pattern of MyoD in the cerebellum and demonstrated a novel tumor suppressor function of 
MyoD in mouse medulloblastoma with potential clinical significance. The next steps are 
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first, to investigate if MyoD can impair tumorigenic potential of human medulloblastoma 
cells and to determine the underlying mechanisms. This question can be addressed by forced 
expression of MyoD in additional medulloblastoma cell lines followed by transplantation 
into recipient mice to monitor tumor initiation and growth and characterize resulting tumors 
in experimental and control groups with markers of proliferation and differentiation. For this 
experiment, I am currently cloning a MyoD lentiviral vector with a fluorescent marker that 
will allow sorting of positively transduced cells prior to transplantation. Second, it remains to 
be determined if endogenous MYOD is expressed at a protein level in a  subset of human 
medulloblastomas. Immunohistochemical detection of MYOD on human medulloblastoma 
tissue has not yielded definitive results due to technical issues. I will carry out Western blot 
analyses as an alternative approach. Third, to identify molecules besides Id3 that are involved 
in the MyoD mediated tumor suppressor network, gene expression profiling from the late 
onset MyoD wt/wt SmoA2 and early onset MyoD -/wt; SmoA2 tumors will be a pertinent 
approach. Third, to determine if MyoD exerts its tumor suppressor effect through Id3, the 
effect of overexpressing and silencing Id3, on tumorigenesis will be studied. Fourth, 
experimental approaches to assess the functional significance of MyoD expression in early 
postnatal development will need to be determined. MyoD possibly does not regulate GNP 
proliferation since histological analyses of cerebellar sections from MyoD -/- , MyoD -/wt 
and MyoD wt/wt does not reveal any apparent differences in GNP number.  
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